FORTISTRYER的个人主页 - 老虎社区

FORTISTRYER

FORTISTRYER

Part time trader, full time

IP属地：未知

236关注

2粉丝

0主题

0勋章

2021-07-27

Seems like it’s coming down

抱歉，原内容已删除

2021-07-21

Great!

Behind The Plunge In Yields: This Is A Growth Story, Not A Rethink Of Inflation

2021-07-16

Good

抱歉，原内容已删除

2021-07-16

😂😂😂

抱歉，原内容已删除

2021-07-05

Good!

5 of the Best Tech Stocks to Buy for July

2021-06-26

Apple

抱歉，原内容已删除

2021-06-26

Apple

抱歉，原内容已删除

2021-06-25

Great!

抱歉，原内容已删除

2021-06-25

Huat Ar!

抱歉，原内容已删除

2021-06-22

Great

5 Ultra-Popular Stocks Wall Street Views as Overvalued

2021-06-21

To the moon!

抱歉，原内容已删除

2021-06-21

Nice piece of info!

Gold Steadies After Posting Biggest Weekly Loss in 15 Months

2021-06-15

Great

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3553149584675358","uuid":"3553149584675358","gmtCreate":1590055561993,"gmtModify":1623808895377,"name":"FORTISTRYER","pinyin":"fortistryer","introduction":"","introductionEn":"","signature":"Part time trader, full time","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":236,"tweetSize":13,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.12.10","exceedPercentage":"93.44%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.17","exceedPercentage":"80.92%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":7,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":809225973,"gmtCreate":1627373936192,"gmtModify":1633765618186,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Seems like it’s coming down&nbsp;","listText":"Seems like it’s coming down&nbsp;","text":"Seems like it’s coming down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/809225973","repostId":"2154596195","repostType":4,"isVote":1,"tweetType":1,"viewCount":128,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178695892,"gmtCreate":1626809709916,"gmtModify":1633770870043,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/178695892","repostId":"1109861258","repostType":4,"repost":{"id":"1109861258","kind":"news","pubTimestamp":1626793354,"share":"https://www.laohu8.com/m/news/1109861258?lang=&edition=full","pubTime":"2021-07-20 23:02","market":"us","language":"en","title":"Behind The Plunge In Yields: This Is A Growth Story, Not A Rethink Of Inflation","url":"https://stock-news.laohu8.com/highlight/detail?id=1109861258","media":"zerohedge","summary":"In a notable turn of events, the overnight session saw an initial attempt at a modest reversal in th","content":"<p>In a notable turn of events, the overnight session saw an initial attempt at a modest reversal in the recent Treasury rally only to be met with further buying interest. The net result was a tick lower in 10-year yields that brought the benchmark to levels not seen since mid-February.</p>\n<p><img src=\"https://static.tigerbbs.com/48f958db8d2903a76ff6541648b287fc\" tg-width=\"1223\" tg-height=\"687\" width=\"100%\" height=\"auto\">With the next technical target sill 5 bps away, we’ll be watching the interplay between risk assets and US rates as the delta-inspired repricing continues. We’re cognizant that the severity of the recent move has led to stretched momentum measures, implying incremental gains will be more difficult to achieve. This isn’t to suggest the floor for rates is evident at the moment, rather that it should be anticipated that the pace of the rally will slow.<b>There has been plenty of chatter surrounding the possibility 10- year yields dip below 1.0%; an eventuality that would be a short-lived endeavor, but not one that’s off the table.</b>More immediately however, will be gauging the extent to which rising case counts can carry yields even lower from here.</p>\n<p><b>It would be an oversimplification to conclude this move is entirely a function of the economic risks posed by the reinstatement of covid-19 restrictions. In fact, we’ll argue the rally has been exaggerated by the Fed’s most recent efforts to be less dovish.</b>Policymakers are in the pre-meeting radio period of radio silence; which eliminates the potential for any official commentary on the Fed’s take on the renewed pandemic risks. Moreover,<b>it leaves investors operating under the assumption that 1) tapering is still on track, 2) rate hikes as early as next year could come to fruition, and 3) the Fed’s ‘will act if not transitory’ stance on inflation remains value</b>. While these surely still hold true to some extent, the implied commitment may be waning given investors’ response to the recent covid developments.</p>\n<p>Headlines this morning conclude ‘markets no longer worried about inflation’; a notion, which is ostensibly consistent with the price action in US rates, misses the mark.<b>10-year breakevens are still at 225 bp and a distance away from the mid-June lows.</b>In addition, rising supply-driven inflation that functions as a tax on consumption as opposed to a reflection of a healthy real economy creates downside risks for the recovery. When combined with concerns that H1 will represent the peak of the rebound, it follows intuitively that the market has moved on to trading the next stage in the cycle – i.e. recalibrating growth expectations in reflecting the new norm; one in which herd immunity will prove elusive and variant risks (delta and others) become an ongoing concern.<b>A quick glance at real yields near -100 bp reinforces the read that this is a growth story, not a collective rethink of reflation.</b></p>\n<p>There is yet another nuance of the price action that merits highlighting. Specifically, the move thus far has questionably been a flattening event as 10s and 30s outperform. The front end of the curve has benefited to a lesser extent as monetary policy expectations have remained in place.<b>This morning however, we’re starting to see the 5-year sector lead the rally. In the event we’re seeing the transition from a longer-term growth story to further pricing out Fed tightening, this could ultimately serve to moderate the gains in 10s and 30s.</b>This isn’t to suggest that less room for the FOMC to eventually normalize policy rates is a compelling reason to sell duration in the face of a resurgence of the pandemic. Instead, confidence that monetary policymakers won’t be so eager to respond to pockets of reflation given the renewed headwinds facing the global recovery</p>\n<p>We’ll be tracking this particular evolution in the nature of the bullish repricing if, for no other reason,<b>it will be instrumental in gauging what to anticipate in response to next week’s FOMC meeting and Powell’s press conference.</b>Note that in light of the +8.1% consensus estimate for next week’s release of Q2 real GDP, there is little question that a strong rebound in H1 is priced in and investors have shifted toward trading the next stage in the recovery that contains far greater uncertainties.</p>\n<p>If the move in real yields is any indication there is growing angst on the rebound; 10-year real rates reached their lowest level since early January and within striking distance of the cycle low at -112.4 bp.</p>\n<p><img src=\"https://static.tigerbbs.com/add9a9864bc513a7f99d365620818f07\" tg-width=\"1223\" tg-height=\"687\" width=\"100%\" height=\"auto\">The decline in reals is made all the more noteworthy given the proximity to Thursday’s $16 bn new issue 10-year TIPS auction. Current valuations demonstrate not only increasing worry on the spread of the delta variant domestically, but perhaps more consequentially, overseas. Whereas there was once a time when the US rates landscape was solely dictated by the domestic fundamentals, the globalization of the economy and markets now leave Treasury yields a function of the global backdrop. This helps account for the impressive round of bullishness and durability of the bid for USTs even as the data has generally continued to perform well. We’re reminded of the time tested adage that resistance hardly holds on the third attempt, and will monitor the -112 bp line in the sand in 10-year real yields over the balance of the week.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Behind The Plunge In Yields: This Is A Growth Story, Not A Rethink Of Inflation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBehind The Plunge In Yields: This Is A Growth Story, Not A Rethink Of Inflation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 23:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/behind-plunge-yields-growth-story-not-rethink-inflation?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In a notable turn of events, the overnight session saw an initial attempt at a modest reversal in the recent Treasury rally only to be met with further buying interest. The net result was a tick lower...</p>\n\n<a href=\"https://www.zerohedge.com/markets/behind-plunge-yields-growth-story-not-rethink-inflation?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","SPY":"标普500ETF"},"source_url":"https://www.zerohedge.com/markets/behind-plunge-yields-growth-story-not-rethink-inflation?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109861258","content_text":"In a notable turn of events, the overnight session saw an initial attempt at a modest reversal in the recent Treasury rally only to be met with further buying interest. The net result was a tick lower in 10-year yields that brought the benchmark to levels not seen since mid-February.\nWith the next technical target sill 5 bps away, we’ll be watching the interplay between risk assets and US rates as the delta-inspired repricing continues. We’re cognizant that the severity of the recent move has led to stretched momentum measures, implying incremental gains will be more difficult to achieve. This isn’t to suggest the floor for rates is evident at the moment, rather that it should be anticipated that the pace of the rally will slow.There has been plenty of chatter surrounding the possibility 10- year yields dip below 1.0%; an eventuality that would be a short-lived endeavor, but not one that’s off the table.More immediately however, will be gauging the extent to which rising case counts can carry yields even lower from here.\nIt would be an oversimplification to conclude this move is entirely a function of the economic risks posed by the reinstatement of covid-19 restrictions. In fact, we’ll argue the rally has been exaggerated by the Fed’s most recent efforts to be less dovish.Policymakers are in the pre-meeting radio period of radio silence; which eliminates the potential for any official commentary on the Fed’s take on the renewed pandemic risks. Moreover,it leaves investors operating under the assumption that 1) tapering is still on track, 2) rate hikes as early as next year could come to fruition, and 3) the Fed’s ‘will act if not transitory’ stance on inflation remains value. While these surely still hold true to some extent, the implied commitment may be waning given investors’ response to the recent covid developments.\nHeadlines this morning conclude ‘markets no longer worried about inflation’; a notion, which is ostensibly consistent with the price action in US rates, misses the mark.10-year breakevens are still at 225 bp and a distance away from the mid-June lows.In addition, rising supply-driven inflation that functions as a tax on consumption as opposed to a reflection of a healthy real economy creates downside risks for the recovery. When combined with concerns that H1 will represent the peak of the rebound, it follows intuitively that the market has moved on to trading the next stage in the cycle – i.e. recalibrating growth expectations in reflecting the new norm; one in which herd immunity will prove elusive and variant risks (delta and others) become an ongoing concern.A quick glance at real yields near -100 bp reinforces the read that this is a growth story, not a collective rethink of reflation.\nThere is yet another nuance of the price action that merits highlighting. Specifically, the move thus far has questionably been a flattening event as 10s and 30s outperform. The front end of the curve has benefited to a lesser extent as monetary policy expectations have remained in place.This morning however, we’re starting to see the 5-year sector lead the rally. In the event we’re seeing the transition from a longer-term growth story to further pricing out Fed tightening, this could ultimately serve to moderate the gains in 10s and 30s.This isn’t to suggest that less room for the FOMC to eventually normalize policy rates is a compelling reason to sell duration in the face of a resurgence of the pandemic. Instead, confidence that monetary policymakers won’t be so eager to respond to pockets of reflation given the renewed headwinds facing the global recovery\nWe’ll be tracking this particular evolution in the nature of the bullish repricing if, for no other reason,it will be instrumental in gauging what to anticipate in response to next week’s FOMC meeting and Powell’s press conference.Note that in light of the +8.1% consensus estimate for next week’s release of Q2 real GDP, there is little question that a strong rebound in H1 is priced in and investors have shifted toward trading the next stage in the recovery that contains far greater uncertainties.\nIf the move in real yields is any indication there is growing angst on the rebound; 10-year real rates reached their lowest level since early January and within striking distance of the cycle low at -112.4 bp.\nThe decline in reals is made all the more noteworthy given the proximity to Thursday’s $16 bn new issue 10-year TIPS auction. Current valuations demonstrate not only increasing worry on the spread of the delta variant domestically, but perhaps more consequentially, overseas. Whereas there was once a time when the US rates landscape was solely dictated by the domestic fundamentals, the globalization of the economy and markets now leave Treasury yields a function of the global backdrop. This helps account for the impressive round of bullishness and durability of the bid for USTs even as the data has generally continued to perform well. We’re reminded of the time tested adage that resistance hardly holds on the third attempt, and will monitor the -112 bp line in the sand in 10-year real yields over the balance of the week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170630231,"gmtCreate":1626425101623,"gmtModify":1633926860055,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/170630231","repostId":"2151147577","repostType":4,"isVote":1,"tweetType":1,"viewCount":165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170630037,"gmtCreate":1626425077129,"gmtModify":1633926860775,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"😂😂😂","listText":"😂😂😂","text":"😂😂😂","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/170630037","repostId":"2151570311","repostType":4,"isVote":1,"tweetType":1,"viewCount":267,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":155670606,"gmtCreate":1625426067505,"gmtModify":1633940834950,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Good!","listText":"Good!","text":"Good!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/155670606","repostId":"1140994998","repostType":4,"repost":{"id":"1140994998","kind":"news","pubTimestamp":1625286969,"share":"https://www.laohu8.com/m/news/1140994998?lang=&edition=full","pubTime":"2021-07-03 12:36","market":"us","language":"en","title":"5 of the Best Tech Stocks to Buy for July","url":"https://stock-news.laohu8.com/highlight/detail?id=1140994998","media":"yahoo","summary":"Tech stocks are back on the upswing.\nIt was a rough spring for the technology sector, as traders ins","content":"<p>Tech stocks are back on the upswing.</p>\n<p>It was a rough spring for the technology sector, as traders instead turned their attention to reopening stocks along withcryptocurrenciesand meme plays. However, now crypto has plunged and reopening stocks are taking on water as well amid a surge in COVID-19 virus variants.</p>\n<p>A recent Federal Reserve decision caused a big swing in interest rates, which has led to investors selling value stocks and buying growth stocks instead. As if that weren't enough, tech got another boost this week as a federal court blocked a key antitrust lawsuit against <a href=\"https://laohu8.com/S/FB\">Facebook</a> (ticker:FB). This has seemingly given the green light to other large tech companies to keep expanding their businesses as well. With all that in place, this is shaping up to be a good summer for tech stocks, including these five in particular:</p>\n<ul>\n <li><a href=\"https://laohu8.com/S/FB\">Facebook</a> (FB)</li>\n <li><a href=\"https://laohu8.com/S/GOOG\">Alphabet</a> (GOOG,GOOGL)</li>\n <li><a href=\"https://laohu8.com/S/BLKB\">Blackbaud</a> (BLKB)</li>\n <li><a href=\"https://laohu8.com/S/JKHY\">Jack Henry &amp; Associates</a> (JKHY)</li>\n <li><a href=\"https://laohu8.com/S/TXN\">Texas Instruments</a> (TXN)</li>\n</ul>\n<p><b>Facebook (FB)</b></p>\n<p>In late June, a federal court dismissed antitrust charges against Facebook. The Federal Trade Commission (FTC) had claimed that Facebook was acting as a monopoly in social media. The FTC, if it had its way, would have tried to force Facebook to divest its other pivotal holdings, including WhatsApp and Instagram, to create a more competitive social media landscape.</p>\n<p>However, the federal court said the FTC failed to prove that Facebook was a monopoly. Facebook stock popped on the news and topped a $1 trillion valuation for the first time.</p>\n<p>Arguably, however, the stock should be up a lot more. Shares are still trading for just 23 times forward earnings while analysts forecast nearly 20% annual revenue growth in 2022 and 2023. Now, with the threat of government intervention gone, Facebook is even more compelling.</p>\n<p><b><a href=\"https://laohu8.com/S/GOOGL\">Alphabet</a> (GOOG,GOOGL)</b></p>\n<p>The court's ruling has broader implications. While Facebook was the target in that case, it's no secret that regulators have been looking at most of the tech titans as potential monopolies, perhaps none more than Alphabet.</p>\n<p>Google's search business has massive market share in online advertising. And the search business is hooked into its operating system and applications such as Gmail to extend its reach. Google's other ventures, such asself-driving carsubsidiary Waymo, could extend Google's domain into next-generation technology as well.</p>\n<p>In announcing a lawsuit against Alphabet last year, Texas' attorney general said that \"if the free market were a baseball game, Google positioned itself as the pitcher, the batter and the umpire.\" Now, however, with Facebook clear of antitrust concerns, it sets a precedent for Google to avoid a major regulatory punishment as well.</p>\n<p>Alphabet stock isn't as cheap as Facebook, but at 26 times forward earnings and approximately 15% projected annual revenue growth, it has earned its spot as <a href=\"https://laohu8.com/S/AONE\">one</a> of the best tech stocks to buy now.</p>\n<p><b>Blackbaud (BLKB)</b></p>\n<p>Blackbaud is a software company focused on charitable organization and K-12 schools. Its primary business is in providing software for charities to receive payments and manage their relationships with donors. The company estimates that 25% of charitable giving in 2020 occurred via Blackbaud's platform.</p>\n<p>Charitable giving was disrupted in 2020 due to the pandemic, though some organizations saw an uptick in activity as people donated in the wake of the twin tragedies of theeconomic recessionand health crisis. Still, 2020 wasn't a great year for Blackbaud. More broadly, Blackbaud has been in transition from on-premise software to a subscription cloud offering.</p>\n<p>Such transitions in tech stocks are often met with stock price weakness as investors grapple with less upfront revenue from the subscription model. That creates opportunity now, however, to buy a leading niche software player at less than 26 times forward earnings with a reopening tailwind as charities can start having in-person events once again.</p>\n<p><b>Jack Henry (JKHY)</b></p>\n<p>Jack Henry is a leading payment processing and informationtechnology company; its main clients are banks and credit unions. The company has an extremely stable business that barely missed a beat even during the financial crisis. Since then, Jack Henry stock has gone up more than 500% thanks to steady growth in the overall demand for payments and financial services.</p>\n<p>That said, Jack Henry stock has gone flat as investors fret over the health of the banking and financial system in the COVID-19 era. More recently, it has become apparent that credit-quality concerns didn't end up causing much material harm to banks. As the economy is picking up in 2021, the banks are roaring back; financials have been <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the top-performing sectors this year.</p>\n<p>With that risk now off the table, Jack Henry is primed to follow suit and blast off to new all-time highs. In addition, the company earns a significant chunk of high-margin business from mergers and acquisitions (M&amp;A) activity in the banking sector. Withbank stockssoaring, M&amp;A is on the rise, and this should directly boost Jack Henry's earnings.</p>\n<p><b>Texas Instruments (TXN)</b></p>\n<p>Texas Instruments is the leader in analogsemiconductor chips. This is a business that focuses on taking real-world parameters such as weather information and converting it into data for digital use. This line of chips is increasingly important as the Internet of Things grows and more devices than ever are online.</p>\n<p>Texas Instruments is making a particularly big push in smart cars, and should sell a large chunk of the chipsets that end up going into autonomous vehicles. In late June, Texas Instruments also announced that it's buying a fabricating unit in Utah from <a href=\"https://laohu8.com/S/MU\">Micron Technology</a> (MU) for $900 million as the company continues to execute on its growth plan.</p>\n<p>Texas Instruments is benefiting from the current semiconductor shortage, which puts it in a good position for better pricing and profit margins going forward. The company has a prodigious growth record, having tripled its earnings per share over the past decade. Now, it trades for just 24 times forward earnings, which is quite reasonable in a bull market for the industry.</p>","source":"lsy1584348713084","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 of the Best Tech Stocks to Buy for July</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 of the Best Tech Stocks to Buy for July\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-03 12:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/5-best-tech-stocks-buy-171937180.html><strong>yahoo</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tech stocks are back on the upswing.\nIt was a rough spring for the technology sector, as traders instead turned their attention to reopening stocks along withcryptocurrenciesand meme plays. However, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/5-best-tech-stocks-buy-171937180.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLKB":"布莱克波特科技","JKHY":"杰克亨利","GOOG":"谷歌","TXN":"德州仪器","GOOGL":"谷歌A"},"source_url":"https://finance.yahoo.com/news/5-best-tech-stocks-buy-171937180.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140994998","content_text":"Tech stocks are back on the upswing.\nIt was a rough spring for the technology sector, as traders instead turned their attention to reopening stocks along withcryptocurrenciesand meme plays. However, now crypto has plunged and reopening stocks are taking on water as well amid a surge in COVID-19 virus variants.\nA recent Federal Reserve decision caused a big swing in interest rates, which has led to investors selling value stocks and buying growth stocks instead. As if that weren't enough, tech got another boost this week as a federal court blocked a key antitrust lawsuit against Facebook (ticker:FB). This has seemingly given the green light to other large tech companies to keep expanding their businesses as well. With all that in place, this is shaping up to be a good summer for tech stocks, including these five in particular:\n\nFacebook (FB)\nAlphabet (GOOG,GOOGL)\nBlackbaud (BLKB)\nJack Henry & Associates (JKHY)\nTexas Instruments (TXN)\n\nFacebook (FB)\nIn late June, a federal court dismissed antitrust charges against Facebook. The Federal Trade Commission (FTC) had claimed that Facebook was acting as a monopoly in social media. The FTC, if it had its way, would have tried to force Facebook to divest its other pivotal holdings, including WhatsApp and Instagram, to create a more competitive social media landscape.\nHowever, the federal court said the FTC failed to prove that Facebook was a monopoly. Facebook stock popped on the news and topped a $1 trillion valuation for the first time.\nArguably, however, the stock should be up a lot more. Shares are still trading for just 23 times forward earnings while analysts forecast nearly 20% annual revenue growth in 2022 and 2023. Now, with the threat of government intervention gone, Facebook is even more compelling.\nAlphabet (GOOG,GOOGL)\nThe court's ruling has broader implications. While Facebook was the target in that case, it's no secret that regulators have been looking at most of the tech titans as potential monopolies, perhaps none more than Alphabet.\nGoogle's search business has massive market share in online advertising. And the search business is hooked into its operating system and applications such as Gmail to extend its reach. Google's other ventures, such asself-driving carsubsidiary Waymo, could extend Google's domain into next-generation technology as well.\nIn announcing a lawsuit against Alphabet last year, Texas' attorney general said that \"if the free market were a baseball game, Google positioned itself as the pitcher, the batter and the umpire.\" Now, however, with Facebook clear of antitrust concerns, it sets a precedent for Google to avoid a major regulatory punishment as well.\nAlphabet stock isn't as cheap as Facebook, but at 26 times forward earnings and approximately 15% projected annual revenue growth, it has earned its spot as one of the best tech stocks to buy now.\nBlackbaud (BLKB)\nBlackbaud is a software company focused on charitable organization and K-12 schools. Its primary business is in providing software for charities to receive payments and manage their relationships with donors. The company estimates that 25% of charitable giving in 2020 occurred via Blackbaud's platform.\nCharitable giving was disrupted in 2020 due to the pandemic, though some organizations saw an uptick in activity as people donated in the wake of the twin tragedies of theeconomic recessionand health crisis. Still, 2020 wasn't a great year for Blackbaud. More broadly, Blackbaud has been in transition from on-premise software to a subscription cloud offering.\nSuch transitions in tech stocks are often met with stock price weakness as investors grapple with less upfront revenue from the subscription model. That creates opportunity now, however, to buy a leading niche software player at less than 26 times forward earnings with a reopening tailwind as charities can start having in-person events once again.\nJack Henry (JKHY)\nJack Henry is a leading payment processing and informationtechnology company; its main clients are banks and credit unions. The company has an extremely stable business that barely missed a beat even during the financial crisis. Since then, Jack Henry stock has gone up more than 500% thanks to steady growth in the overall demand for payments and financial services.\nThat said, Jack Henry stock has gone flat as investors fret over the health of the banking and financial system in the COVID-19 era. More recently, it has become apparent that credit-quality concerns didn't end up causing much material harm to banks. As the economy is picking up in 2021, the banks are roaring back; financials have been one of the top-performing sectors this year.\nWith that risk now off the table, Jack Henry is primed to follow suit and blast off to new all-time highs. In addition, the company earns a significant chunk of high-margin business from mergers and acquisitions (M&A) activity in the banking sector. Withbank stockssoaring, M&A is on the rise, and this should directly boost Jack Henry's earnings.\nTexas Instruments (TXN)\nTexas Instruments is the leader in analogsemiconductor chips. This is a business that focuses on taking real-world parameters such as weather information and converting it into data for digital use. This line of chips is increasingly important as the Internet of Things grows and more devices than ever are online.\nTexas Instruments is making a particularly big push in smart cars, and should sell a large chunk of the chipsets that end up going into autonomous vehicles. In late June, Texas Instruments also announced that it's buying a fabricating unit in Utah from Micron Technology (MU) for $900 million as the company continues to execute on its growth plan.\nTexas Instruments is benefiting from the current semiconductor shortage, which puts it in a good position for better pricing and profit margins going forward. The company has a prodigious growth record, having tripled its earnings per share over the past decade. Now, it trades for just 24 times forward earnings, which is quite reasonable in a bull market for the industry.","news_type":1},"isVote":1,"tweetType":1,"viewCount":207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125846356,"gmtCreate":1624669211275,"gmtModify":1633949878136,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Apple","listText":"Apple","text":"Apple","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/125846356","repostId":"2146071375","repostType":4,"isVote":1,"tweetType":1,"viewCount":246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125848226,"gmtCreate":1624669199165,"gmtModify":1633949878384,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Apple","listText":"Apple","text":"Apple","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/125848226","repostId":"2146071375","repostType":4,"isVote":1,"tweetType":1,"viewCount":450,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126797809,"gmtCreate":1624583927601,"gmtModify":1633950952261,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Great!&nbsp;","listText":"Great!&nbsp;","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/126797809","repostId":"1160256327","repostType":4,"isVote":1,"tweetType":1,"viewCount":274,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126813000,"gmtCreate":1624550728900,"gmtModify":1634004453417,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Huat Ar!&nbsp;","listText":"Huat Ar!&nbsp;","text":"Huat Ar!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126813000","repostId":"1155360226","repostType":4,"isVote":1,"tweetType":1,"viewCount":700,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120369457,"gmtCreate":1624300617579,"gmtModify":1634008160525,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/120369457","repostId":"2145084835","repostType":4,"repost":{"id":"2145084835","kind":"highlight","pubTimestamp":1624280460,"share":"https://www.laohu8.com/m/news/2145084835?lang=&edition=full","pubTime":"2021-06-21 21:01","market":"us","language":"en","title":"5 Ultra-Popular Stocks Wall Street Views as Overvalued","url":"https://stock-news.laohu8.com/highlight/detail?id=2145084835","media":"Motley Fool","summary":"If analysts are correct, these high-flying stocks will fizzle out over the next year.","content":"<p>Generally speaking, it pays to be bullish on Wall Street. Despite navigating its way through Black Monday in 1987, the dot-com bubble, the Great Recession, and more recently the coronavirus crash, the average annual total return for the benchmark <b>S&amp;P 500</b> since 1980, including dividends, is north of 11%.</p>\n<p>Not surprisingly, we see this optimism readily apparent in Wall Street's ratings on stocks. According to <b>FactSet</b>, more than half of all stocks carry a consensus buy rating, 38% have the equivalent of a hold rating, and just 7% are rated as sells. Yet, history shows that far more than 7% of stocks will eventually head lower.</p>\n<p>Based on Wall Street's consensus price targets, the following five ultra-popular stocks are all expected to lose value over the coming 12 months.</p>\n<p><img src=\"https://static.tigerbbs.com/b04ade705354c4825038c4dfcd0187d9\" tg-width=\"700\" tg-height=\"500\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Palantir Technologies: Implied downside of 12%</h3>\n<p>Since its direct listing in late September 2020, data-mining company <b>Palantir Technologies</b> (NYSE:PLTR) has been a favorite among growth and retail investors. But if Wall Street's <a href=\"https://laohu8.com/S/AONE\">one</a>-year consensus price target proves accurate, Palantir will head in reverse by up to 12%.</p>\n<p>The likeliest reason Wall Street is tempering expectations on Palantir is valuation. Specifically, Palantir ended June 17 with a market cap of nearly $48 billion, but is on track to bring in perhaps $1.5 billion in full-year sales in 2021. That's a multiple of about 32 times sales. Even if Palantir continues to grow its top-line at 30% annually, it could take years for this price-to-sales multiple to come down to anywhere close to the average for cloud stocks.</p>\n<p>Another possible concern is the growth potential for its government-focused Gotham platform. Big government contract wins in the U.S. have been primarily responsible for Palantir's exceptional growth rate. However, there remains an outside chance that President Joe Biden may curb funding to some of the federal agencies that employ Palantir's services.</p>\n<p>Over the long run, I'm optimistic and believe Palantir's platform is unlike anything else available. But tempering near-term expectations given its valuation premium may be warranted.</p>\n<p><img src=\"https://static.tigerbbs.com/a38605bee8e62f3e8aa414fa24278e7e\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Moderna: Implied downside of 11%</h3>\n<p>Biotech stock <b>Moderna</b> (NASDAQ:MRNA) is arguably the biggest beneficiary of the coronavirus disease 2019 (COVID-19) pandemic. It's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only three drugmakers to currently have their COVID-19 vaccine approved on an emergency-use authorization (EUA) basis in the United States. But if Wall Street's consensus 12-month price target is correct, it's stock is also on its way to a double-digit decline.</p>\n<p>Why the lack of love from Wall Street? The answer looks to be analysts looking to the future. While Moderna's COVID-19 vaccine is a mainstay in the U.S., and it's likely to play a clear role in other markets, time might prove the company's enemy. Over time, new vaccines are expected to come onto the scene, which'll eat away at Moderna's potential pool of patients.</p>\n<p>The other worry is that no one is exactly certain how long COVID-19 vaccine immunity will last. If it's a year, Moderna is unlikely to be the only drugmaker supplying booster shots. Meanwhile, if it's longer than a year, it means reduced sales opportunities for the company.</p>\n<p>Based solely on Wall Street's earnings per share consensus in 2021 and 2022, Moderna appears reasonably priced. But with the company staring down a potentially significant haircut in revenue next year as new drugmakers enter the space, caution is advised.</p>\n<p><img src=\"https://static.tigerbbs.com/07841e6a8173146a0fbfddf95a0f1ccb\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>GameStop: Implied downside of 71%</h3>\n<p>This will probably come as a shock to no one, but Reddit favorite <b>GameStop</b> (NYSE:GME) is fully expected to fall flat on its face. Even though Wall Street's consensus price target for the company has quintupled in recent months, it <i>still</i> implies up to 71% downside over the next year.</p>\n<p>The biggest issue for GameStop is that its valuation has completely detached from its underlying fundamentals. While it's not uncommon for stocks to trade on emotion for short periods of time, operating performance is what always dictates the long-term movement in the share price of a stock. When it comes to operating performance, GameStop has been a dud.</p>\n<p>Although the company's first-quarter fiscal results highlighted a 25% net sales increase from the prior-year period, total sales for the company have been falling precipitously for years. That's because video game retailer GameStop recognized the shift to digital gaming too late, and it's now stuck with its massive portfolio of brick-and-mortar gaming stores. Even though e-commerce sales have been a bright spot for the company, slashing costs and closing stores remains its No. 1 priority.</p>\n<p>With sufficient cash, bankruptcy isn't a concern for GameStop. But without any true top-line growth and the company still losing money, it's an impossible sell at its current price tag.</p>\n<p><img src=\"https://static.tigerbbs.com/c7ff785aa0040a5565d474390f58b47a\" tg-width=\"700\" tg-height=\"457\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Ocugen: Implied downside of 18%</h3>\n<p>Volatile clinical-stage biotech stock <b>Ocugen</b> (NASDAQ:OCGN) may also be in for an unpleasant next 12 months. The company behind an experimental COVID-19 vaccine (Covaxin) and a trio of internally developed eye-blindness candidates is expected to shed 18% of its value, if Wall Street's consensus price target is correct.</p>\n<p>Arguably the biggest issue for Ocugen is the clinical update the company issued on June 10 concerning Covaxin. Even though partner Bharat Biotech led a large clinical study in India that yielded an overall efficacy of 78%, along with 100% efficacy in preventing severe forms of COVID-19, Ocugen announced on June 10 that it would forgo seeking an EUA in the U.S. and would instead file for a biologics license application. In other words, Ocugen's path to a quick emergency approval in the U.S. just flew out the window.</p>\n<p>What's more, the U.S. Food and Drug Administration's requested additional information and data on Covaxin. This is a fancy of saying that Ocugen will very likely have to run a clinical study in the U.S. prior to submitting Covaxin for approval. That means added costs and an even longer wait before Ocugen has a chance to penetrate the lucrative U.S. market.</p>\n<p>Though it's impossible to predict how long COVID-19 vaccine immunity will last, Ocugen's chances of being a significant player in the U.S. COVID-19 vaccine space are dwindling.</p>\n<p><img src=\"https://static.tigerbbs.com/91f6037829ea3fb0ae1cae0b95d8d11e\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>NVIDIA: Implied downside of 3%</h3>\n<p>Don't adjust your computer, laptop, or smartphone screens -- that really says <b>NVIDIA</b> (NASDAQ:NVDA). Following its incredible run higher (NVIDIA has doubled over the past year), graphics processing unit giant NVIDIA closed 3% above Wall Street's consensus price target, as of June 17.</p>\n<p>One reason for tempered expectations at this point has to be valuation. Even with NVIDIA crushing expectations and seeing strong PC gaming demand, sales growth is expected to slow from an estimated 49% in fiscal 2022 to a high single digit percentage in each of the next two fiscal years. In fact, the company closed at nearly 20 times projected sales for the current fiscal year. That's a bit optimistic given an expected sales growth slowdown.</p>\n<p>Perhaps the other reason Wall Street expects NVIDIA to go sideways is the company's cryptocurrency mining chip segment. While sales of crypto chips could hit $400 million in the current quarter, demand is entirely dependent on the hype surrounding digital currencies and the favorability of technical charts. Crypto is just as well known for its long bear markets as it is for the big gains it's delivered over the past decade. If another lull strikes, a fast-growing ancillary segment for NVIDA could easily become a drag.</p>\n<p>For what it's worth, I see no fundamental reasons to sell NVIDIA if you're already a long-term shareholder. But if you're on the outside looking in, I don't exactly see $746 as an attractive entry point, either.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks Wall Street Views as Overvalued</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks Wall Street Views as Overvalued\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 21:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/21/5-ultra-popular-stocks-wall-street-view-overvalued/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Generally speaking, it pays to be bullish on Wall Street. Despite navigating its way through Black Monday in 1987, the dot-com bubble, the Great Recession, and more recently the coronavirus crash, the...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/21/5-ultra-popular-stocks-wall-street-view-overvalued/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PLTR":"Palantir Technologies Inc.","GME":"游戏驿站","NVDA":"英伟达","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/21/5-ultra-popular-stocks-wall-street-view-overvalued/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145084835","content_text":"Generally speaking, it pays to be bullish on Wall Street. Despite navigating its way through Black Monday in 1987, the dot-com bubble, the Great Recession, and more recently the coronavirus crash, the average annual total return for the benchmark S&P 500 since 1980, including dividends, is north of 11%.\nNot surprisingly, we see this optimism readily apparent in Wall Street's ratings on stocks. According to FactSet, more than half of all stocks carry a consensus buy rating, 38% have the equivalent of a hold rating, and just 7% are rated as sells. Yet, history shows that far more than 7% of stocks will eventually head lower.\nBased on Wall Street's consensus price targets, the following five ultra-popular stocks are all expected to lose value over the coming 12 months.\n\nImage source: Getty Images.\nPalantir Technologies: Implied downside of 12%\nSince its direct listing in late September 2020, data-mining company Palantir Technologies (NYSE:PLTR) has been a favorite among growth and retail investors. But if Wall Street's one-year consensus price target proves accurate, Palantir will head in reverse by up to 12%.\nThe likeliest reason Wall Street is tempering expectations on Palantir is valuation. Specifically, Palantir ended June 17 with a market cap of nearly $48 billion, but is on track to bring in perhaps $1.5 billion in full-year sales in 2021. That's a multiple of about 32 times sales. Even if Palantir continues to grow its top-line at 30% annually, it could take years for this price-to-sales multiple to come down to anywhere close to the average for cloud stocks.\nAnother possible concern is the growth potential for its government-focused Gotham platform. Big government contract wins in the U.S. have been primarily responsible for Palantir's exceptional growth rate. However, there remains an outside chance that President Joe Biden may curb funding to some of the federal agencies that employ Palantir's services.\nOver the long run, I'm optimistic and believe Palantir's platform is unlike anything else available. But tempering near-term expectations given its valuation premium may be warranted.\n\nImage source: Getty Images.\nModerna: Implied downside of 11%\nBiotech stock Moderna (NASDAQ:MRNA) is arguably the biggest beneficiary of the coronavirus disease 2019 (COVID-19) pandemic. It's one of only three drugmakers to currently have their COVID-19 vaccine approved on an emergency-use authorization (EUA) basis in the United States. But if Wall Street's consensus 12-month price target is correct, it's stock is also on its way to a double-digit decline.\nWhy the lack of love from Wall Street? The answer looks to be analysts looking to the future. While Moderna's COVID-19 vaccine is a mainstay in the U.S., and it's likely to play a clear role in other markets, time might prove the company's enemy. Over time, new vaccines are expected to come onto the scene, which'll eat away at Moderna's potential pool of patients.\nThe other worry is that no one is exactly certain how long COVID-19 vaccine immunity will last. If it's a year, Moderna is unlikely to be the only drugmaker supplying booster shots. Meanwhile, if it's longer than a year, it means reduced sales opportunities for the company.\nBased solely on Wall Street's earnings per share consensus in 2021 and 2022, Moderna appears reasonably priced. But with the company staring down a potentially significant haircut in revenue next year as new drugmakers enter the space, caution is advised.\n\nImage source: Getty Images.\nGameStop: Implied downside of 71%\nThis will probably come as a shock to no one, but Reddit favorite GameStop (NYSE:GME) is fully expected to fall flat on its face. Even though Wall Street's consensus price target for the company has quintupled in recent months, it still implies up to 71% downside over the next year.\nThe biggest issue for GameStop is that its valuation has completely detached from its underlying fundamentals. While it's not uncommon for stocks to trade on emotion for short periods of time, operating performance is what always dictates the long-term movement in the share price of a stock. When it comes to operating performance, GameStop has been a dud.\nAlthough the company's first-quarter fiscal results highlighted a 25% net sales increase from the prior-year period, total sales for the company have been falling precipitously for years. That's because video game retailer GameStop recognized the shift to digital gaming too late, and it's now stuck with its massive portfolio of brick-and-mortar gaming stores. Even though e-commerce sales have been a bright spot for the company, slashing costs and closing stores remains its No. 1 priority.\nWith sufficient cash, bankruptcy isn't a concern for GameStop. But without any true top-line growth and the company still losing money, it's an impossible sell at its current price tag.\n\nImage source: Getty Images.\nOcugen: Implied downside of 18%\nVolatile clinical-stage biotech stock Ocugen (NASDAQ:OCGN) may also be in for an unpleasant next 12 months. The company behind an experimental COVID-19 vaccine (Covaxin) and a trio of internally developed eye-blindness candidates is expected to shed 18% of its value, if Wall Street's consensus price target is correct.\nArguably the biggest issue for Ocugen is the clinical update the company issued on June 10 concerning Covaxin. Even though partner Bharat Biotech led a large clinical study in India that yielded an overall efficacy of 78%, along with 100% efficacy in preventing severe forms of COVID-19, Ocugen announced on June 10 that it would forgo seeking an EUA in the U.S. and would instead file for a biologics license application. In other words, Ocugen's path to a quick emergency approval in the U.S. just flew out the window.\nWhat's more, the U.S. Food and Drug Administration's requested additional information and data on Covaxin. This is a fancy of saying that Ocugen will very likely have to run a clinical study in the U.S. prior to submitting Covaxin for approval. That means added costs and an even longer wait before Ocugen has a chance to penetrate the lucrative U.S. market.\nThough it's impossible to predict how long COVID-19 vaccine immunity will last, Ocugen's chances of being a significant player in the U.S. COVID-19 vaccine space are dwindling.\n\nImage source: Getty Images.\nNVIDIA: Implied downside of 3%\nDon't adjust your computer, laptop, or smartphone screens -- that really says NVIDIA (NASDAQ:NVDA). Following its incredible run higher (NVIDIA has doubled over the past year), graphics processing unit giant NVIDIA closed 3% above Wall Street's consensus price target, as of June 17.\nOne reason for tempered expectations at this point has to be valuation. Even with NVIDIA crushing expectations and seeing strong PC gaming demand, sales growth is expected to slow from an estimated 49% in fiscal 2022 to a high single digit percentage in each of the next two fiscal years. In fact, the company closed at nearly 20 times projected sales for the current fiscal year. That's a bit optimistic given an expected sales growth slowdown.\nPerhaps the other reason Wall Street expects NVIDIA to go sideways is the company's cryptocurrency mining chip segment. While sales of crypto chips could hit $400 million in the current quarter, demand is entirely dependent on the hype surrounding digital currencies and the favorability of technical charts. Crypto is just as well known for its long bear markets as it is for the big gains it's delivered over the past decade. If another lull strikes, a fast-growing ancillary segment for NVIDA could easily become a drag.\nFor what it's worth, I see no fundamental reasons to sell NVIDIA if you're already a long-term shareholder. But if you're on the outside looking in, I don't exactly see $746 as an attractive entry point, either.","news_type":1},"isVote":1,"tweetType":1,"viewCount":455,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167745064,"gmtCreate":1624286315658,"gmtModify":1634008361648,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"To the moon!","listText":"To the moon!","text":"To the moon!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167745064","repostId":"1132601414","repostType":4,"isVote":1,"tweetType":1,"viewCount":160,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167163294,"gmtCreate":1624252677118,"gmtModify":1634008833695,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Nice piece of info!","listText":"Nice piece of info!","text":"Nice piece of info!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167163294","repostId":"1124609704","repostType":4,"repost":{"id":"1124609704","kind":"news","pubTimestamp":1624238429,"share":"https://www.laohu8.com/m/news/1124609704?lang=&edition=full","pubTime":"2021-06-21 09:20","market":"fut","language":"en","title":"Gold Steadies After Posting Biggest Weekly Loss in 15 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1124609704","media":"bloomberg","summary":"Gold steadied after posting the biggest weekly loss in 15 months as the Federal Reserve’s hawkish sh","content":"<p>Gold steadied after posting the biggest weekly loss in 15 months as the Federal Reserve’s hawkish shift damped reflation bets.</p>\n<p>Inflation risksmay warrantthe U.S. central bank beginning raising interest rates next year, St. Louis Fed President James Bullard said Friday. His comments came after last week’s Fed meeting where officials signaled monetary policy tightening could start earlier than expected, with Chair Jerome Powell saying that the Fed would begin a discussion about scaling back bond purchases used to support financial markets and the economy during the pandemic.</p>\n<p><img src=\"https://static.tigerbbs.com/fc269bfd6438429e7f1bd15ec2aa60a1\" tg-width=\"930\" tg-height=\"523\" referrerpolicy=\"no-referrer\"></p>\n<p>Bullion has been weighed down by concerns over tighter monetary policy, although Powellcautionedthat discussions about raising interest rates would be “highly premature.” He’s due to testify at a House Subcommittee hearing on the Fed’s pandemic emergency lending and its asset purchase programs Tuesday.</p>\n<p>Spot gold rose 0.2% to $1,768.45 an ounce at 7:24 a.m. in Singapore. Prices fell 6% last week, the most since March 2020. Silver, palladium and platinum all advanced. The Bloomberg Dollar Spot Index steadied after rising 2% last week.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gold Steadies After Posting Biggest Weekly Loss in 15 Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGold Steadies After Posting Biggest Weekly Loss in 15 Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 09:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-06-21/gold-steadies-after-posting-biggest-weekly-loss-in-15-months><strong>bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gold steadied after posting the biggest weekly loss in 15 months as the Federal Reserve’s hawkish shift damped reflation bets.\nInflation risksmay warrantthe U.S. central bank beginning raising ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-21/gold-steadies-after-posting-biggest-weekly-loss-in-15-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GOLD":"巴里克黄金"},"source_url":"https://www.bloomberg.com/news/articles/2021-06-21/gold-steadies-after-posting-biggest-weekly-loss-in-15-months","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124609704","content_text":"Gold steadied after posting the biggest weekly loss in 15 months as the Federal Reserve’s hawkish shift damped reflation bets.\nInflation risksmay warrantthe U.S. central bank beginning raising interest rates next year, St. Louis Fed President James Bullard said Friday. His comments came after last week’s Fed meeting where officials signaled monetary policy tightening could start earlier than expected, with Chair Jerome Powell saying that the Fed would begin a discussion about scaling back bond purchases used to support financial markets and the economy during the pandemic.\n\nBullion has been weighed down by concerns over tighter monetary policy, although Powellcautionedthat discussions about raising interest rates would be “highly premature.” He’s due to testify at a House Subcommittee hearing on the Fed’s pandemic emergency lending and its asset purchase programs Tuesday.\nSpot gold rose 0.2% to $1,768.45 an ounce at 7:24 a.m. in Singapore. Prices fell 6% last week, the most since March 2020. Silver, palladium and platinum all advanced. The Bloomberg Dollar Spot Index steadied after rising 2% last week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":270,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187118943,"gmtCreate":1623746210482,"gmtModify":1634029218468,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187118943","repostId":"1175897310","repostType":4,"isVote":1,"tweetType":1,"viewCount":211,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":178695892,"gmtCreate":1626809709916,"gmtModify":1633770870043,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Great!","listText":"Great!","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/178695892","repostId":"1109861258","repostType":4,"repost":{"id":"1109861258","kind":"news","pubTimestamp":1626793354,"share":"https://www.laohu8.com/m/news/1109861258?lang=&edition=full","pubTime":"2021-07-20 23:02","market":"us","language":"en","title":"Behind The Plunge In Yields: This Is A Growth Story, Not A Rethink Of Inflation","url":"https://stock-news.laohu8.com/highlight/detail?id=1109861258","media":"zerohedge","summary":"In a notable turn of events, the overnight session saw an initial attempt at a modest reversal in th","content":"<p>In a notable turn of events, the overnight session saw an initial attempt at a modest reversal in the recent Treasury rally only to be met with further buying interest. The net result was a tick lower in 10-year yields that brought the benchmark to levels not seen since mid-February.</p>\n<p><img src=\"https://static.tigerbbs.com/48f958db8d2903a76ff6541648b287fc\" tg-width=\"1223\" tg-height=\"687\" width=\"100%\" height=\"auto\">With the next technical target sill 5 bps away, we’ll be watching the interplay between risk assets and US rates as the delta-inspired repricing continues. We’re cognizant that the severity of the recent move has led to stretched momentum measures, implying incremental gains will be more difficult to achieve. This isn’t to suggest the floor for rates is evident at the moment, rather that it should be anticipated that the pace of the rally will slow.<b>There has been plenty of chatter surrounding the possibility 10- year yields dip below 1.0%; an eventuality that would be a short-lived endeavor, but not one that’s off the table.</b>More immediately however, will be gauging the extent to which rising case counts can carry yields even lower from here.</p>\n<p><b>It would be an oversimplification to conclude this move is entirely a function of the economic risks posed by the reinstatement of covid-19 restrictions. In fact, we’ll argue the rally has been exaggerated by the Fed’s most recent efforts to be less dovish.</b>Policymakers are in the pre-meeting radio period of radio silence; which eliminates the potential for any official commentary on the Fed’s take on the renewed pandemic risks. Moreover,<b>it leaves investors operating under the assumption that 1) tapering is still on track, 2) rate hikes as early as next year could come to fruition, and 3) the Fed’s ‘will act if not transitory’ stance on inflation remains value</b>. While these surely still hold true to some extent, the implied commitment may be waning given investors’ response to the recent covid developments.</p>\n<p>Headlines this morning conclude ‘markets no longer worried about inflation’; a notion, which is ostensibly consistent with the price action in US rates, misses the mark.<b>10-year breakevens are still at 225 bp and a distance away from the mid-June lows.</b>In addition, rising supply-driven inflation that functions as a tax on consumption as opposed to a reflection of a healthy real economy creates downside risks for the recovery. When combined with concerns that H1 will represent the peak of the rebound, it follows intuitively that the market has moved on to trading the next stage in the cycle – i.e. recalibrating growth expectations in reflecting the new norm; one in which herd immunity will prove elusive and variant risks (delta and others) become an ongoing concern.<b>A quick glance at real yields near -100 bp reinforces the read that this is a growth story, not a collective rethink of reflation.</b></p>\n<p>There is yet another nuance of the price action that merits highlighting. Specifically, the move thus far has questionably been a flattening event as 10s and 30s outperform. The front end of the curve has benefited to a lesser extent as monetary policy expectations have remained in place.<b>This morning however, we’re starting to see the 5-year sector lead the rally. In the event we’re seeing the transition from a longer-term growth story to further pricing out Fed tightening, this could ultimately serve to moderate the gains in 10s and 30s.</b>This isn’t to suggest that less room for the FOMC to eventually normalize policy rates is a compelling reason to sell duration in the face of a resurgence of the pandemic. Instead, confidence that monetary policymakers won’t be so eager to respond to pockets of reflation given the renewed headwinds facing the global recovery</p>\n<p>We’ll be tracking this particular evolution in the nature of the bullish repricing if, for no other reason,<b>it will be instrumental in gauging what to anticipate in response to next week’s FOMC meeting and Powell’s press conference.</b>Note that in light of the +8.1% consensus estimate for next week’s release of Q2 real GDP, there is little question that a strong rebound in H1 is priced in and investors have shifted toward trading the next stage in the recovery that contains far greater uncertainties.</p>\n<p>If the move in real yields is any indication there is growing angst on the rebound; 10-year real rates reached their lowest level since early January and within striking distance of the cycle low at -112.4 bp.</p>\n<p><img src=\"https://static.tigerbbs.com/add9a9864bc513a7f99d365620818f07\" tg-width=\"1223\" tg-height=\"687\" width=\"100%\" height=\"auto\">The decline in reals is made all the more noteworthy given the proximity to Thursday’s $16 bn new issue 10-year TIPS auction. Current valuations demonstrate not only increasing worry on the spread of the delta variant domestically, but perhaps more consequentially, overseas. Whereas there was once a time when the US rates landscape was solely dictated by the domestic fundamentals, the globalization of the economy and markets now leave Treasury yields a function of the global backdrop. This helps account for the impressive round of bullishness and durability of the bid for USTs even as the data has generally continued to perform well. We’re reminded of the time tested adage that resistance hardly holds on the third attempt, and will monitor the -112 bp line in the sand in 10-year real yields over the balance of the week.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Behind The Plunge In Yields: This Is A Growth Story, Not A Rethink Of Inflation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBehind The Plunge In Yields: This Is A Growth Story, Not A Rethink Of Inflation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-20 23:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/behind-plunge-yields-growth-story-not-rethink-inflation?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In a notable turn of events, the overnight session saw an initial attempt at a modest reversal in the recent Treasury rally only to be met with further buying interest. The net result was a tick lower...</p>\n\n<a href=\"https://www.zerohedge.com/markets/behind-plunge-yields-growth-story-not-rethink-inflation?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","SPY":"标普500ETF"},"source_url":"https://www.zerohedge.com/markets/behind-plunge-yields-growth-story-not-rethink-inflation?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109861258","content_text":"In a notable turn of events, the overnight session saw an initial attempt at a modest reversal in the recent Treasury rally only to be met with further buying interest. The net result was a tick lower in 10-year yields that brought the benchmark to levels not seen since mid-February.\nWith the next technical target sill 5 bps away, we’ll be watching the interplay between risk assets and US rates as the delta-inspired repricing continues. We’re cognizant that the severity of the recent move has led to stretched momentum measures, implying incremental gains will be more difficult to achieve. This isn’t to suggest the floor for rates is evident at the moment, rather that it should be anticipated that the pace of the rally will slow.There has been plenty of chatter surrounding the possibility 10- year yields dip below 1.0%; an eventuality that would be a short-lived endeavor, but not one that’s off the table.More immediately however, will be gauging the extent to which rising case counts can carry yields even lower from here.\nIt would be an oversimplification to conclude this move is entirely a function of the economic risks posed by the reinstatement of covid-19 restrictions. In fact, we’ll argue the rally has been exaggerated by the Fed’s most recent efforts to be less dovish.Policymakers are in the pre-meeting radio period of radio silence; which eliminates the potential for any official commentary on the Fed’s take on the renewed pandemic risks. Moreover,it leaves investors operating under the assumption that 1) tapering is still on track, 2) rate hikes as early as next year could come to fruition, and 3) the Fed’s ‘will act if not transitory’ stance on inflation remains value. While these surely still hold true to some extent, the implied commitment may be waning given investors’ response to the recent covid developments.\nHeadlines this morning conclude ‘markets no longer worried about inflation’; a notion, which is ostensibly consistent with the price action in US rates, misses the mark.10-year breakevens are still at 225 bp and a distance away from the mid-June lows.In addition, rising supply-driven inflation that functions as a tax on consumption as opposed to a reflection of a healthy real economy creates downside risks for the recovery. When combined with concerns that H1 will represent the peak of the rebound, it follows intuitively that the market has moved on to trading the next stage in the cycle – i.e. recalibrating growth expectations in reflecting the new norm; one in which herd immunity will prove elusive and variant risks (delta and others) become an ongoing concern.A quick glance at real yields near -100 bp reinforces the read that this is a growth story, not a collective rethink of reflation.\nThere is yet another nuance of the price action that merits highlighting. Specifically, the move thus far has questionably been a flattening event as 10s and 30s outperform. The front end of the curve has benefited to a lesser extent as monetary policy expectations have remained in place.This morning however, we’re starting to see the 5-year sector lead the rally. In the event we’re seeing the transition from a longer-term growth story to further pricing out Fed tightening, this could ultimately serve to moderate the gains in 10s and 30s.This isn’t to suggest that less room for the FOMC to eventually normalize policy rates is a compelling reason to sell duration in the face of a resurgence of the pandemic. Instead, confidence that monetary policymakers won’t be so eager to respond to pockets of reflation given the renewed headwinds facing the global recovery\nWe’ll be tracking this particular evolution in the nature of the bullish repricing if, for no other reason,it will be instrumental in gauging what to anticipate in response to next week’s FOMC meeting and Powell’s press conference.Note that in light of the +8.1% consensus estimate for next week’s release of Q2 real GDP, there is little question that a strong rebound in H1 is priced in and investors have shifted toward trading the next stage in the recovery that contains far greater uncertainties.\nIf the move in real yields is any indication there is growing angst on the rebound; 10-year real rates reached their lowest level since early January and within striking distance of the cycle low at -112.4 bp.\nThe decline in reals is made all the more noteworthy given the proximity to Thursday’s $16 bn new issue 10-year TIPS auction. Current valuations demonstrate not only increasing worry on the spread of the delta variant domestically, but perhaps more consequentially, overseas. Whereas there was once a time when the US rates landscape was solely dictated by the domestic fundamentals, the globalization of the economy and markets now leave Treasury yields a function of the global backdrop. This helps account for the impressive round of bullishness and durability of the bid for USTs even as the data has generally continued to perform well. We’re reminded of the time tested adage that resistance hardly holds on the third attempt, and will monitor the -112 bp line in the sand in 10-year real yields over the balance of the week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":809225973,"gmtCreate":1627373936192,"gmtModify":1633765618186,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Seems like it’s coming down&nbsp;","listText":"Seems like it’s coming down&nbsp;","text":"Seems like it’s coming down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/809225973","repostId":"2154596195","repostType":4,"isVote":1,"tweetType":1,"viewCount":128,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167745064,"gmtCreate":1624286315658,"gmtModify":1634008361648,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"To the moon!","listText":"To the moon!","text":"To the moon!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167745064","repostId":"1132601414","repostType":4,"repost":{"id":"1132601414","kind":"news","pubTimestamp":1624284919,"share":"https://www.laohu8.com/m/news/1132601414?lang=&edition=full","pubTime":"2021-06-21 22:15","market":"us","language":"en","title":"ContextLogic Has More Than Just Meme Status to Power Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=1132601414","media":"InvestorPlace","summary":"Consider this context before selling WISH stock.\n\nContextLogic rose neraly 6% in morning trading.\n\nC","content":"<blockquote>\n Consider this context before selling WISH stock.\n</blockquote>\n<p>ContextLogic rose neraly 6% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f667d82ef8232c33e7c7fa81b2ca1f27\" tg-width=\"728\" tg-height=\"498\" referrerpolicy=\"no-referrer\"></p>\n<p><b>ContextLogic</b>(NASDAQ:<b><u>WISH</u></b>) stock has not turned out as well as a lot of people had hoped.</p>\n<p>Shares initially opened trading last December around $20 and quickly advanced 50%.</p>\n<p>Since then, however, WISH stock has been in freefall, with shares falling 75% in the span of a few months. It will open this morning at around $11.40.</p>\n<p>Finally, though, there’s hope for better days. The r/WallStreetBets crowd recently discovered WISH stock and shares doubled shortly thereafter.</p>\n<p>The usual reasons applied. It has a great ticker symbol, high short interest, and a compelling value proposition for consumers. Add it all up, and it’s not hard to see why Reddit took a liking to WISH stock.</p>\n<p>Question is, will ContextLogic be a flash in the pan for meme traders? Or is this move going to have real sticking power? I’m inclined toward the latter option.</p>\n<p>While ContextLogic has some real pressing questions it will need to answer over time, there’s the foundations of a good business.</p>\n<p><b>Digital Treasure Hunt and WISH Stock</b></p>\n<p>ContextLogic, which operates Wish.com, has an intriguing business model. It essentially serves as a sort of online flea market or dollar store.</p>\n<p>Its motto is “Shopping made fun” and it backs that up. Wish frequently offers discounts in the 70-90% range. It’s a bargain hunter’s paradise.</p>\n<p>Wish has products from manufacturers with very low operating costs, such as from firms based in China. These products then sell to buyers in other markets, offering a sort of geographical arbitrage.</p>\n<p>These products sometimes have some problems. Consumers wanting consistently high-quality merchandise probably want to look elsewhere. However, Wish.com offers products at rock bottom prices, and oftentimes the quality greatly exceeds what you’d expect to receive at that sort of price point.</p>\n<p>It’s a bit of a hit-or-miss experience. But with such low prices, it’s hardly a big deal when the occasional order misfires. And when you find something cool on Wish at a great price, it can be a euphoric experience.</p>\n<p>ContextLogic has members of management that were high-ups at<b>Alphabet</b>(NASDAQ:<b><u>GOOGL</u></b>) and&nbsp;<b>AirBnb</b>(NASDAQ:<b><u>ABNB</u></b>). Don’t let the discount online marketplace business fool you, Wish is a sophisticated operation.</p>\n<p><b>Weak Stock Price Performance</b></p>\n<p>Wish may have waited a quarter too long to perform its initial public offering (IPO). By the time WISH stock started trading in December 2020, traders were already selling e-commerce stocks to buy economic reopening trades.</p>\n<p>The time for e-commerce stocks was last summer or fall, not 2021.</p>\n<p>ContextLogic also reported a pretty ugly quarter in May. The company’s earnings fell short of expectations. It also offered revenue guidance below expectations.</p>\n<p>Revenues grew 76% year-over-year, which is great. However, its core revenue growth of 40% was much slower and gave investors pause.</p>\n<p>These results aren’t a disaster for the company. It’s a young firm with fast growth, even if that growth was a little below expectations. Still, management will need to start beating estimates again if it wants to get a sustained rally in its share price going.</p>\n<p>Short squeezes are great, but long-term investors will want to see a stronger fundamental picture before committing too heavily to WISH stock.</p>\n<p>WISH Stock Verdict</p>\n<p>A lot of traders are wishing that they had sold ContextLogic stock during the big run-up last week. The move from $8 up to $15 in a couple of days was quite a remarkable one indeed. Profit-takers have sent the stock back down significantly since then.</p>\n<p>However, there’s a decent chance that WISH stock still has another big surge ahead of it. The fact is that shares weren’t too pricey before the short squeeze excitement kicked off.</p>\n<p>As such, there should still be plenty of opportunities for buyers here around $11. Shares were at $32 in February, after all. So, if you like the company, don’t let the short-term price volatility worry you too much.</p>\n<p>As our Luke Lango argued, there’sa lot more to ContextLogicthan your average meme stock, and the price hasn’t moved too far off the lows yet.</p>\n<p>The company may need to deliver better quarterly results before the stock really explodes to the upside. However, the core business model is intriguing enough and appears to be catching on with consumers.</p>\n<p>That plus some meme magic could make WISH stock worth holding.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ContextLogic Has More Than Just Meme Status to Power Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nContextLogic Has More Than Just Meme Status to Power Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 22:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/wish-stock-has-more-than-just-meme-status-to-power-gains/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Consider this context before selling WISH stock.\n\nContextLogic rose neraly 6% in morning trading.\n\nContextLogic(NASDAQ:WISH) stock has not turned out as well as a lot of people had hoped.\nShares ...</p>\n\n<a href=\"https://investorplace.com/2021/06/wish-stock-has-more-than-just-meme-status-to-power-gains/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/wish-stock-has-more-than-just-meme-status-to-power-gains/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132601414","content_text":"Consider this context before selling WISH stock.\n\nContextLogic rose neraly 6% in morning trading.\n\nContextLogic(NASDAQ:WISH) stock has not turned out as well as a lot of people had hoped.\nShares initially opened trading last December around $20 and quickly advanced 50%.\nSince then, however, WISH stock has been in freefall, with shares falling 75% in the span of a few months. It will open this morning at around $11.40.\nFinally, though, there’s hope for better days. The r/WallStreetBets crowd recently discovered WISH stock and shares doubled shortly thereafter.\nThe usual reasons applied. It has a great ticker symbol, high short interest, and a compelling value proposition for consumers. Add it all up, and it’s not hard to see why Reddit took a liking to WISH stock.\nQuestion is, will ContextLogic be a flash in the pan for meme traders? Or is this move going to have real sticking power? I’m inclined toward the latter option.\nWhile ContextLogic has some real pressing questions it will need to answer over time, there’s the foundations of a good business.\nDigital Treasure Hunt and WISH Stock\nContextLogic, which operates Wish.com, has an intriguing business model. It essentially serves as a sort of online flea market or dollar store.\nIts motto is “Shopping made fun” and it backs that up. Wish frequently offers discounts in the 70-90% range. It’s a bargain hunter’s paradise.\nWish has products from manufacturers with very low operating costs, such as from firms based in China. These products then sell to buyers in other markets, offering a sort of geographical arbitrage.\nThese products sometimes have some problems. Consumers wanting consistently high-quality merchandise probably want to look elsewhere. However, Wish.com offers products at rock bottom prices, and oftentimes the quality greatly exceeds what you’d expect to receive at that sort of price point.\nIt’s a bit of a hit-or-miss experience. But with such low prices, it’s hardly a big deal when the occasional order misfires. And when you find something cool on Wish at a great price, it can be a euphoric experience.\nContextLogic has members of management that were high-ups atAlphabet(NASDAQ:GOOGL) and AirBnb(NASDAQ:ABNB). Don’t let the discount online marketplace business fool you, Wish is a sophisticated operation.\nWeak Stock Price Performance\nWish may have waited a quarter too long to perform its initial public offering (IPO). By the time WISH stock started trading in December 2020, traders were already selling e-commerce stocks to buy economic reopening trades.\nThe time for e-commerce stocks was last summer or fall, not 2021.\nContextLogic also reported a pretty ugly quarter in May. The company’s earnings fell short of expectations. It also offered revenue guidance below expectations.\nRevenues grew 76% year-over-year, which is great. However, its core revenue growth of 40% was much slower and gave investors pause.\nThese results aren’t a disaster for the company. It’s a young firm with fast growth, even if that growth was a little below expectations. Still, management will need to start beating estimates again if it wants to get a sustained rally in its share price going.\nShort squeezes are great, but long-term investors will want to see a stronger fundamental picture before committing too heavily to WISH stock.\nWISH Stock Verdict\nA lot of traders are wishing that they had sold ContextLogic stock during the big run-up last week. The move from $8 up to $15 in a couple of days was quite a remarkable one indeed. Profit-takers have sent the stock back down significantly since then.\nHowever, there’s a decent chance that WISH stock still has another big surge ahead of it. The fact is that shares weren’t too pricey before the short squeeze excitement kicked off.\nAs such, there should still be plenty of opportunities for buyers here around $11. Shares were at $32 in February, after all. So, if you like the company, don’t let the short-term price volatility worry you too much.\nAs our Luke Lango argued, there’sa lot more to ContextLogicthan your average meme stock, and the price hasn’t moved too far off the lows yet.\nThe company may need to deliver better quarterly results before the stock really explodes to the upside. However, the core business model is intriguing enough and appears to be catching on with consumers.\nThat plus some meme magic could make WISH stock worth holding.","news_type":1},"isVote":1,"tweetType":1,"viewCount":160,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170630231,"gmtCreate":1626425101623,"gmtModify":1633926860055,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/170630231","repostId":"2151147577","repostType":4,"repost":{"id":"2151147577","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626414359,"share":"https://www.laohu8.com/m/news/2151147577?lang=&edition=full","pubTime":"2021-07-16 13:45","market":"hk","language":"en","title":"HK Exchanges jumps on report HK IPOs to be exempt from cybersecurity reviews","url":"https://stock-news.laohu8.com/highlight/detail?id=2151147577","media":"Reuters","summary":"** Shares of Hong Kong Exchanges and Clearing rise as much as 5.1% to HK$531, their highest since Fe","content":"<p>** Shares of Hong Kong Exchanges and Clearing rise as much as 5.1% to HK$531, their highest since Feb. 24</p>\n<p>** Stock of the city's bourse operator is on track for its best day since July 7; the biggest percentage gainer in Hang Seng Finance Index and the second biggest percentage gainer in the benchmark Hang Seng Index</p>\n<p>** Stock is the third most actively traded by turnover, and the fifth biggest percentage gainer in Hong Kong composite Industry Index tracking financials stocks</p>\n<p>** China plans to exempt companies going public in Hong Kong from reviews by the country's cybersecurity regulator, removing <a href=\"https://laohu8.com/S/AONE.U\">one</a> hurdle for businesses that list in the Asian financial hub instead of the U.S., Bloomberg News reported citing people familiar with the matter</p>\n<p>** Bankers briefed by the CSRC came away with the impression that the approval process for Hong Kong would be less onerous than for the U.S., the report added</p>\n<p>** The Hong Kong composite Industry Index tracking financials stocks climbs 0.5%</p>\n<p>** The Hang Seng Finance Index gains 0.7%, and the benchmark Hang Seng Index climbs 0.5%</p>\n<p>** The stock had risen 18.8% this year, as of last close</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Exchanges jumps on report HK IPOs to be exempt from cybersecurity reviews</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Exchanges jumps on report HK IPOs to be exempt from cybersecurity reviews\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-16 13:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of Hong Kong Exchanges and Clearing rise as much as 5.1% to HK$531, their highest since Feb. 24</p>\n<p>** Stock of the city's bourse operator is on track for its best day since July 7; the biggest percentage gainer in Hang Seng Finance Index and the second biggest percentage gainer in the benchmark Hang Seng Index</p>\n<p>** Stock is the third most actively traded by turnover, and the fifth biggest percentage gainer in Hong Kong composite Industry Index tracking financials stocks</p>\n<p>** China plans to exempt companies going public in Hong Kong from reviews by the country's cybersecurity regulator, removing <a href=\"https://laohu8.com/S/AONE.U\">one</a> hurdle for businesses that list in the Asian financial hub instead of the U.S., Bloomberg News reported citing people familiar with the matter</p>\n<p>** Bankers briefed by the CSRC came away with the impression that the approval process for Hong Kong would be less onerous than for the U.S., the report added</p>\n<p>** The Hong Kong composite Industry Index tracking financials stocks climbs 0.5%</p>\n<p>** The Hang Seng Finance Index gains 0.7%, and the benchmark Hang Seng Index climbs 0.5%</p>\n<p>** The stock had risen 18.8% this year, as of last close</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"00388":"香港交易所"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151147577","content_text":"** Shares of Hong Kong Exchanges and Clearing rise as much as 5.1% to HK$531, their highest since Feb. 24\n** Stock of the city's bourse operator is on track for its best day since July 7; the biggest percentage gainer in Hang Seng Finance Index and the second biggest percentage gainer in the benchmark Hang Seng Index\n** Stock is the third most actively traded by turnover, and the fifth biggest percentage gainer in Hong Kong composite Industry Index tracking financials stocks\n** China plans to exempt companies going public in Hong Kong from reviews by the country's cybersecurity regulator, removing one hurdle for businesses that list in the Asian financial hub instead of the U.S., Bloomberg News reported citing people familiar with the matter\n** Bankers briefed by the CSRC came away with the impression that the approval process for Hong Kong would be less onerous than for the U.S., the report added\n** The Hong Kong composite Industry Index tracking financials stocks climbs 0.5%\n** The Hang Seng Finance Index gains 0.7%, and the benchmark Hang Seng Index climbs 0.5%\n** The stock had risen 18.8% this year, as of last close","news_type":1},"isVote":1,"tweetType":1,"viewCount":165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170630037,"gmtCreate":1626425077129,"gmtModify":1633926860775,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"😂😂😂","listText":"😂😂😂","text":"😂😂😂","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/170630037","repostId":"2151570311","repostType":4,"repost":{"id":"2151570311","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626416350,"share":"https://www.laohu8.com/m/news/2151570311?lang=&edition=full","pubTime":"2021-07-16 14:19","market":"hk","language":"en","title":"HK's Hutchmed jumps as EMA accepts drug application for tumor treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2151570311","media":"Reuters","summary":"** Shares of oncology and immunology drug developer and maker Hutchmed (China) Ltd surge 12.2% to HK","content":"<p>** Shares of oncology and immunology drug developer and maker Hutchmed (China) Ltd surge 12.2% to HK$67.95, on course for the best day since listing on June 30</p>\n<p>** Stock hit the highest since July 2, and on track for second session of gains</p>\n<p>** CK Hutchison backed biopharmaceutical firm says the European Medicines Agency (EMA) has accepted its marketing authorization application for surufatinib for the treatment of pancreatic and extra-pancreatic neuroendocrine tumors</p>\n<p>** Says the EMA's validation confirms that the submission is sufficiently complete and it is ready to commence the formal review process, and the company hopes to soon be able to bring the treatment to patients across the U.S. and Europe</p>\n<p>** The Hong Kong Hang Seng Commerce &amp; Industry Index gains 0.3%, while the healthcare index slips 0.6%</p>\n<p>** The benchmark Hang Seng Index climbs 0.3%</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK's Hutchmed jumps as EMA accepts drug application for tumor treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK's Hutchmed jumps as EMA accepts drug application for tumor treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-16 14:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>** Shares of oncology and immunology drug developer and maker Hutchmed (China) Ltd surge 12.2% to HK$67.95, on course for the best day since listing on June 30</p>\n<p>** Stock hit the highest since July 2, and on track for second session of gains</p>\n<p>** CK Hutchison backed biopharmaceutical firm says the European Medicines Agency (EMA) has accepted its marketing authorization application for surufatinib for the treatment of pancreatic and extra-pancreatic neuroendocrine tumors</p>\n<p>** Says the EMA's validation confirms that the submission is sufficiently complete and it is ready to commence the formal review process, and the company hopes to soon be able to bring the treatment to patients across the U.S. and Europe</p>\n<p>** The Hong Kong Hang Seng Commerce &amp; Industry Index gains 0.3%, while the healthcare index slips 0.6%</p>\n<p>** The benchmark Hang Seng Index climbs 0.3%</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"00001":"长和","00013":"和黄医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151570311","content_text":"** Shares of oncology and immunology drug developer and maker Hutchmed (China) Ltd surge 12.2% to HK$67.95, on course for the best day since listing on June 30\n** Stock hit the highest since July 2, and on track for second session of gains\n** CK Hutchison backed biopharmaceutical firm says the European Medicines Agency (EMA) has accepted its marketing authorization application for surufatinib for the treatment of pancreatic and extra-pancreatic neuroendocrine tumors\n** Says the EMA's validation confirms that the submission is sufficiently complete and it is ready to commence the formal review process, and the company hopes to soon be able to bring the treatment to patients across the U.S. and Europe\n** The Hong Kong Hang Seng Commerce & Industry Index gains 0.3%, while the healthcare index slips 0.6%\n** The benchmark Hang Seng Index climbs 0.3%","news_type":1},"isVote":1,"tweetType":1,"viewCount":267,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":155670606,"gmtCreate":1625426067505,"gmtModify":1633940834950,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Good!","listText":"Good!","text":"Good!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/155670606","repostId":"1140994998","repostType":4,"repost":{"id":"1140994998","kind":"news","pubTimestamp":1625286969,"share":"https://www.laohu8.com/m/news/1140994998?lang=&edition=full","pubTime":"2021-07-03 12:36","market":"us","language":"en","title":"5 of the Best Tech Stocks to Buy for July","url":"https://stock-news.laohu8.com/highlight/detail?id=1140994998","media":"yahoo","summary":"Tech stocks are back on the upswing.\nIt was a rough spring for the technology sector, as traders ins","content":"<p>Tech stocks are back on the upswing.</p>\n<p>It was a rough spring for the technology sector, as traders instead turned their attention to reopening stocks along withcryptocurrenciesand meme plays. However, now crypto has plunged and reopening stocks are taking on water as well amid a surge in COVID-19 virus variants.</p>\n<p>A recent Federal Reserve decision caused a big swing in interest rates, which has led to investors selling value stocks and buying growth stocks instead. As if that weren't enough, tech got another boost this week as a federal court blocked a key antitrust lawsuit against <a href=\"https://laohu8.com/S/FB\">Facebook</a> (ticker:FB). This has seemingly given the green light to other large tech companies to keep expanding their businesses as well. With all that in place, this is shaping up to be a good summer for tech stocks, including these five in particular:</p>\n<ul>\n <li><a href=\"https://laohu8.com/S/FB\">Facebook</a> (FB)</li>\n <li><a href=\"https://laohu8.com/S/GOOG\">Alphabet</a> (GOOG,GOOGL)</li>\n <li><a href=\"https://laohu8.com/S/BLKB\">Blackbaud</a> (BLKB)</li>\n <li><a href=\"https://laohu8.com/S/JKHY\">Jack Henry &amp; Associates</a> (JKHY)</li>\n <li><a href=\"https://laohu8.com/S/TXN\">Texas Instruments</a> (TXN)</li>\n</ul>\n<p><b>Facebook (FB)</b></p>\n<p>In late June, a federal court dismissed antitrust charges against Facebook. The Federal Trade Commission (FTC) had claimed that Facebook was acting as a monopoly in social media. The FTC, if it had its way, would have tried to force Facebook to divest its other pivotal holdings, including WhatsApp and Instagram, to create a more competitive social media landscape.</p>\n<p>However, the federal court said the FTC failed to prove that Facebook was a monopoly. Facebook stock popped on the news and topped a $1 trillion valuation for the first time.</p>\n<p>Arguably, however, the stock should be up a lot more. Shares are still trading for just 23 times forward earnings while analysts forecast nearly 20% annual revenue growth in 2022 and 2023. Now, with the threat of government intervention gone, Facebook is even more compelling.</p>\n<p><b><a href=\"https://laohu8.com/S/GOOGL\">Alphabet</a> (GOOG,GOOGL)</b></p>\n<p>The court's ruling has broader implications. While Facebook was the target in that case, it's no secret that regulators have been looking at most of the tech titans as potential monopolies, perhaps none more than Alphabet.</p>\n<p>Google's search business has massive market share in online advertising. And the search business is hooked into its operating system and applications such as Gmail to extend its reach. Google's other ventures, such asself-driving carsubsidiary Waymo, could extend Google's domain into next-generation technology as well.</p>\n<p>In announcing a lawsuit against Alphabet last year, Texas' attorney general said that \"if the free market were a baseball game, Google positioned itself as the pitcher, the batter and the umpire.\" Now, however, with Facebook clear of antitrust concerns, it sets a precedent for Google to avoid a major regulatory punishment as well.</p>\n<p>Alphabet stock isn't as cheap as Facebook, but at 26 times forward earnings and approximately 15% projected annual revenue growth, it has earned its spot as <a href=\"https://laohu8.com/S/AONE\">one</a> of the best tech stocks to buy now.</p>\n<p><b>Blackbaud (BLKB)</b></p>\n<p>Blackbaud is a software company focused on charitable organization and K-12 schools. Its primary business is in providing software for charities to receive payments and manage their relationships with donors. The company estimates that 25% of charitable giving in 2020 occurred via Blackbaud's platform.</p>\n<p>Charitable giving was disrupted in 2020 due to the pandemic, though some organizations saw an uptick in activity as people donated in the wake of the twin tragedies of theeconomic recessionand health crisis. Still, 2020 wasn't a great year for Blackbaud. More broadly, Blackbaud has been in transition from on-premise software to a subscription cloud offering.</p>\n<p>Such transitions in tech stocks are often met with stock price weakness as investors grapple with less upfront revenue from the subscription model. That creates opportunity now, however, to buy a leading niche software player at less than 26 times forward earnings with a reopening tailwind as charities can start having in-person events once again.</p>\n<p><b>Jack Henry (JKHY)</b></p>\n<p>Jack Henry is a leading payment processing and informationtechnology company; its main clients are banks and credit unions. The company has an extremely stable business that barely missed a beat even during the financial crisis. Since then, Jack Henry stock has gone up more than 500% thanks to steady growth in the overall demand for payments and financial services.</p>\n<p>That said, Jack Henry stock has gone flat as investors fret over the health of the banking and financial system in the COVID-19 era. More recently, it has become apparent that credit-quality concerns didn't end up causing much material harm to banks. As the economy is picking up in 2021, the banks are roaring back; financials have been <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the top-performing sectors this year.</p>\n<p>With that risk now off the table, Jack Henry is primed to follow suit and blast off to new all-time highs. In addition, the company earns a significant chunk of high-margin business from mergers and acquisitions (M&amp;A) activity in the banking sector. Withbank stockssoaring, M&amp;A is on the rise, and this should directly boost Jack Henry's earnings.</p>\n<p><b>Texas Instruments (TXN)</b></p>\n<p>Texas Instruments is the leader in analogsemiconductor chips. This is a business that focuses on taking real-world parameters such as weather information and converting it into data for digital use. This line of chips is increasingly important as the Internet of Things grows and more devices than ever are online.</p>\n<p>Texas Instruments is making a particularly big push in smart cars, and should sell a large chunk of the chipsets that end up going into autonomous vehicles. In late June, Texas Instruments also announced that it's buying a fabricating unit in Utah from <a href=\"https://laohu8.com/S/MU\">Micron Technology</a> (MU) for $900 million as the company continues to execute on its growth plan.</p>\n<p>Texas Instruments is benefiting from the current semiconductor shortage, which puts it in a good position for better pricing and profit margins going forward. The company has a prodigious growth record, having tripled its earnings per share over the past decade. Now, it trades for just 24 times forward earnings, which is quite reasonable in a bull market for the industry.</p>","source":"lsy1584348713084","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 of the Best Tech Stocks to Buy for July</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 of the Best Tech Stocks to Buy for July\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-03 12:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/5-best-tech-stocks-buy-171937180.html><strong>yahoo</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tech stocks are back on the upswing.\nIt was a rough spring for the technology sector, as traders instead turned their attention to reopening stocks along withcryptocurrenciesand meme plays. However, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/5-best-tech-stocks-buy-171937180.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLKB":"布莱克波特科技","JKHY":"杰克亨利","GOOG":"谷歌","TXN":"德州仪器","GOOGL":"谷歌A"},"source_url":"https://finance.yahoo.com/news/5-best-tech-stocks-buy-171937180.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140994998","content_text":"Tech stocks are back on the upswing.\nIt was a rough spring for the technology sector, as traders instead turned their attention to reopening stocks along withcryptocurrenciesand meme plays. However, now crypto has plunged and reopening stocks are taking on water as well amid a surge in COVID-19 virus variants.\nA recent Federal Reserve decision caused a big swing in interest rates, which has led to investors selling value stocks and buying growth stocks instead. As if that weren't enough, tech got another boost this week as a federal court blocked a key antitrust lawsuit against Facebook (ticker:FB). This has seemingly given the green light to other large tech companies to keep expanding their businesses as well. With all that in place, this is shaping up to be a good summer for tech stocks, including these five in particular:\n\nFacebook (FB)\nAlphabet (GOOG,GOOGL)\nBlackbaud (BLKB)\nJack Henry & Associates (JKHY)\nTexas Instruments (TXN)\n\nFacebook (FB)\nIn late June, a federal court dismissed antitrust charges against Facebook. The Federal Trade Commission (FTC) had claimed that Facebook was acting as a monopoly in social media. The FTC, if it had its way, would have tried to force Facebook to divest its other pivotal holdings, including WhatsApp and Instagram, to create a more competitive social media landscape.\nHowever, the federal court said the FTC failed to prove that Facebook was a monopoly. Facebook stock popped on the news and topped a $1 trillion valuation for the first time.\nArguably, however, the stock should be up a lot more. Shares are still trading for just 23 times forward earnings while analysts forecast nearly 20% annual revenue growth in 2022 and 2023. Now, with the threat of government intervention gone, Facebook is even more compelling.\nAlphabet (GOOG,GOOGL)\nThe court's ruling has broader implications. While Facebook was the target in that case, it's no secret that regulators have been looking at most of the tech titans as potential monopolies, perhaps none more than Alphabet.\nGoogle's search business has massive market share in online advertising. And the search business is hooked into its operating system and applications such as Gmail to extend its reach. Google's other ventures, such asself-driving carsubsidiary Waymo, could extend Google's domain into next-generation technology as well.\nIn announcing a lawsuit against Alphabet last year, Texas' attorney general said that \"if the free market were a baseball game, Google positioned itself as the pitcher, the batter and the umpire.\" Now, however, with Facebook clear of antitrust concerns, it sets a precedent for Google to avoid a major regulatory punishment as well.\nAlphabet stock isn't as cheap as Facebook, but at 26 times forward earnings and approximately 15% projected annual revenue growth, it has earned its spot as one of the best tech stocks to buy now.\nBlackbaud (BLKB)\nBlackbaud is a software company focused on charitable organization and K-12 schools. Its primary business is in providing software for charities to receive payments and manage their relationships with donors. The company estimates that 25% of charitable giving in 2020 occurred via Blackbaud's platform.\nCharitable giving was disrupted in 2020 due to the pandemic, though some organizations saw an uptick in activity as people donated in the wake of the twin tragedies of theeconomic recessionand health crisis. Still, 2020 wasn't a great year for Blackbaud. More broadly, Blackbaud has been in transition from on-premise software to a subscription cloud offering.\nSuch transitions in tech stocks are often met with stock price weakness as investors grapple with less upfront revenue from the subscription model. That creates opportunity now, however, to buy a leading niche software player at less than 26 times forward earnings with a reopening tailwind as charities can start having in-person events once again.\nJack Henry (JKHY)\nJack Henry is a leading payment processing and informationtechnology company; its main clients are banks and credit unions. The company has an extremely stable business that barely missed a beat even during the financial crisis. Since then, Jack Henry stock has gone up more than 500% thanks to steady growth in the overall demand for payments and financial services.\nThat said, Jack Henry stock has gone flat as investors fret over the health of the banking and financial system in the COVID-19 era. More recently, it has become apparent that credit-quality concerns didn't end up causing much material harm to banks. As the economy is picking up in 2021, the banks are roaring back; financials have been one of the top-performing sectors this year.\nWith that risk now off the table, Jack Henry is primed to follow suit and blast off to new all-time highs. In addition, the company earns a significant chunk of high-margin business from mergers and acquisitions (M&A) activity in the banking sector. Withbank stockssoaring, M&A is on the rise, and this should directly boost Jack Henry's earnings.\nTexas Instruments (TXN)\nTexas Instruments is the leader in analogsemiconductor chips. This is a business that focuses on taking real-world parameters such as weather information and converting it into data for digital use. This line of chips is increasingly important as the Internet of Things grows and more devices than ever are online.\nTexas Instruments is making a particularly big push in smart cars, and should sell a large chunk of the chipsets that end up going into autonomous vehicles. In late June, Texas Instruments also announced that it's buying a fabricating unit in Utah from Micron Technology (MU) for $900 million as the company continues to execute on its growth plan.\nTexas Instruments is benefiting from the current semiconductor shortage, which puts it in a good position for better pricing and profit margins going forward. The company has a prodigious growth record, having tripled its earnings per share over the past decade. Now, it trades for just 24 times forward earnings, which is quite reasonable in a bull market for the industry.","news_type":1},"isVote":1,"tweetType":1,"viewCount":207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126797809,"gmtCreate":1624583927601,"gmtModify":1633950952261,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Great!&nbsp;","listText":"Great!&nbsp;","text":"Great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/126797809","repostId":"1160256327","repostType":4,"isVote":1,"tweetType":1,"viewCount":274,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125846356,"gmtCreate":1624669211275,"gmtModify":1633949878136,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Apple","listText":"Apple","text":"Apple","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/125846356","repostId":"2146071375","repostType":4,"isVote":1,"tweetType":1,"viewCount":246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126813000,"gmtCreate":1624550728900,"gmtModify":1634004453417,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Huat Ar!&nbsp;","listText":"Huat Ar!&nbsp;","text":"Huat Ar!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126813000","repostId":"1155360226","repostType":4,"repost":{"id":"1155360226","kind":"news","pubTimestamp":1624542060,"share":"https://www.laohu8.com/m/news/1155360226?lang=&edition=full","pubTime":"2021-06-24 21:41","market":"us","language":"en","title":"Electric vehicle stocks rally as Green Tidal Wave hopes are recharged","url":"https://stock-news.laohu8.com/highlight/detail?id=1155360226","media":"seekingalpha","summary":"Electric vehicle stocks are gaining again in early action in a move that is being attributed to progress with the infrastructure deal in D.C.That is recharging the Green Tidal Wave vibe that was pretty common from Wall Street earlier in the year. Morgan Stanley analyst Adam Jonas noted previously that the EV infrastructure bill could include purchase incentives for EVs, development of charging and manufacturing infrastructure, grid enhancement, etc. - which could all disproportionately benefit T","content":"<p>Electric vehicle stocks are gaining again in early action in a move that is being attributed to progress with the infrastructure deal in D.C.</p>\n<p>That is recharging the Green Tidal Wave vibe that was pretty common from Wall Street earlier in the year. Morgan Stanley analyst Adam Jonas noted previously that the EV infrastructure bill could include purchase incentives for EVs, development of charging and manufacturing infrastructure, grid enhancement, etc. - which could all disproportionately benefit Tesla and pure BEV startups in the near term. Wedbush Securities analyst Dan Ives and team forecast the EV market represents a $5 trillion total addressable market over the next decade with many EV OEMs/supply chain players poised to be major winners.</p>\n<p>EV gainers morning&nbsp;trading: Tesla(NASDAQ:TSLA)+2.37%, Fisker, Workhorse Group, Lordstown Motors, Canoo(NASDAQ:GOEV), Churchill Capital Corp IV-Lucid(NYSE:CCIV), ChargePoint Holdings(NYSE:CHPT), Li Auto(NASDAQ:LI)+0.15%, Nio(NYSE:NIO)+2.09%, QuantumScape(NYSE:QS).</p>\n<p><img src=\"https://static.tigerbbs.com/17d4392ca5f5a0bf408ca43a9138a562\" tg-width=\"280\" tg-height=\"246\"></p>\n<p></p>\n<p>Electrification is a big part of the story now in Detroit as well. General Motors(NYSE:GM)is&nbsp;0.70% higher&nbsp;and Ford(NYSE:F)is&nbsp;up 0.88%.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Electric vehicle stocks rally as Green Tidal Wave hopes are recharged</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElectric vehicle stocks rally as Green Tidal Wave hopes are recharged\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 21:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3709543-electric-vehicle-stocks-rally-as-green-tidal-wave-hopes-are-recharged><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Electric vehicle stocks are gaining again in early action in a move that is being attributed to progress with the infrastructure deal in D.C.\nThat is recharging the Green Tidal Wave vibe that was ...</p>\n\n<a href=\"https://seekingalpha.com/news/3709543-electric-vehicle-stocks-rally-as-green-tidal-wave-hopes-are-recharged\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","TSLA":"特斯拉","XPEV":"小鹏汽车","LI":"理想汽车"},"source_url":"https://seekingalpha.com/news/3709543-electric-vehicle-stocks-rally-as-green-tidal-wave-hopes-are-recharged","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1155360226","content_text":"Electric vehicle stocks are gaining again in early action in a move that is being attributed to progress with the infrastructure deal in D.C.\nThat is recharging the Green Tidal Wave vibe that was pretty common from Wall Street earlier in the year. Morgan Stanley analyst Adam Jonas noted previously that the EV infrastructure bill could include purchase incentives for EVs, development of charging and manufacturing infrastructure, grid enhancement, etc. - which could all disproportionately benefit Tesla and pure BEV startups in the near term. Wedbush Securities analyst Dan Ives and team forecast the EV market represents a $5 trillion total addressable market over the next decade with many EV OEMs/supply chain players poised to be major winners.\nEV gainers morning trading: Tesla(NASDAQ:TSLA)+2.37%, Fisker, Workhorse Group, Lordstown Motors, Canoo(NASDAQ:GOEV), Churchill Capital Corp IV-Lucid(NYSE:CCIV), ChargePoint Holdings(NYSE:CHPT), Li Auto(NASDAQ:LI)+0.15%, Nio(NYSE:NIO)+2.09%, QuantumScape(NYSE:QS).\n\n\nElectrification is a big part of the story now in Detroit as well. General Motors(NYSE:GM)is 0.70% higher and Ford(NYSE:F)is up 0.88%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":700,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120369457,"gmtCreate":1624300617579,"gmtModify":1634008160525,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/120369457","repostId":"2145084835","repostType":4,"repost":{"id":"2145084835","kind":"highlight","pubTimestamp":1624280460,"share":"https://www.laohu8.com/m/news/2145084835?lang=&edition=full","pubTime":"2021-06-21 21:01","market":"us","language":"en","title":"5 Ultra-Popular Stocks Wall Street Views as Overvalued","url":"https://stock-news.laohu8.com/highlight/detail?id=2145084835","media":"Motley Fool","summary":"If analysts are correct, these high-flying stocks will fizzle out over the next year.","content":"<p>Generally speaking, it pays to be bullish on Wall Street. Despite navigating its way through Black Monday in 1987, the dot-com bubble, the Great Recession, and more recently the coronavirus crash, the average annual total return for the benchmark <b>S&amp;P 500</b> since 1980, including dividends, is north of 11%.</p>\n<p>Not surprisingly, we see this optimism readily apparent in Wall Street's ratings on stocks. According to <b>FactSet</b>, more than half of all stocks carry a consensus buy rating, 38% have the equivalent of a hold rating, and just 7% are rated as sells. Yet, history shows that far more than 7% of stocks will eventually head lower.</p>\n<p>Based on Wall Street's consensus price targets, the following five ultra-popular stocks are all expected to lose value over the coming 12 months.</p>\n<p><img src=\"https://static.tigerbbs.com/b04ade705354c4825038c4dfcd0187d9\" tg-width=\"700\" tg-height=\"500\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Palantir Technologies: Implied downside of 12%</h3>\n<p>Since its direct listing in late September 2020, data-mining company <b>Palantir Technologies</b> (NYSE:PLTR) has been a favorite among growth and retail investors. But if Wall Street's <a href=\"https://laohu8.com/S/AONE\">one</a>-year consensus price target proves accurate, Palantir will head in reverse by up to 12%.</p>\n<p>The likeliest reason Wall Street is tempering expectations on Palantir is valuation. Specifically, Palantir ended June 17 with a market cap of nearly $48 billion, but is on track to bring in perhaps $1.5 billion in full-year sales in 2021. That's a multiple of about 32 times sales. Even if Palantir continues to grow its top-line at 30% annually, it could take years for this price-to-sales multiple to come down to anywhere close to the average for cloud stocks.</p>\n<p>Another possible concern is the growth potential for its government-focused Gotham platform. Big government contract wins in the U.S. have been primarily responsible for Palantir's exceptional growth rate. However, there remains an outside chance that President Joe Biden may curb funding to some of the federal agencies that employ Palantir's services.</p>\n<p>Over the long run, I'm optimistic and believe Palantir's platform is unlike anything else available. But tempering near-term expectations given its valuation premium may be warranted.</p>\n<p><img src=\"https://static.tigerbbs.com/a38605bee8e62f3e8aa414fa24278e7e\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Moderna: Implied downside of 11%</h3>\n<p>Biotech stock <b>Moderna</b> (NASDAQ:MRNA) is arguably the biggest beneficiary of the coronavirus disease 2019 (COVID-19) pandemic. It's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of only three drugmakers to currently have their COVID-19 vaccine approved on an emergency-use authorization (EUA) basis in the United States. But if Wall Street's consensus 12-month price target is correct, it's stock is also on its way to a double-digit decline.</p>\n<p>Why the lack of love from Wall Street? The answer looks to be analysts looking to the future. While Moderna's COVID-19 vaccine is a mainstay in the U.S., and it's likely to play a clear role in other markets, time might prove the company's enemy. Over time, new vaccines are expected to come onto the scene, which'll eat away at Moderna's potential pool of patients.</p>\n<p>The other worry is that no one is exactly certain how long COVID-19 vaccine immunity will last. If it's a year, Moderna is unlikely to be the only drugmaker supplying booster shots. Meanwhile, if it's longer than a year, it means reduced sales opportunities for the company.</p>\n<p>Based solely on Wall Street's earnings per share consensus in 2021 and 2022, Moderna appears reasonably priced. But with the company staring down a potentially significant haircut in revenue next year as new drugmakers enter the space, caution is advised.</p>\n<p><img src=\"https://static.tigerbbs.com/07841e6a8173146a0fbfddf95a0f1ccb\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>GameStop: Implied downside of 71%</h3>\n<p>This will probably come as a shock to no one, but Reddit favorite <b>GameStop</b> (NYSE:GME) is fully expected to fall flat on its face. Even though Wall Street's consensus price target for the company has quintupled in recent months, it <i>still</i> implies up to 71% downside over the next year.</p>\n<p>The biggest issue for GameStop is that its valuation has completely detached from its underlying fundamentals. While it's not uncommon for stocks to trade on emotion for short periods of time, operating performance is what always dictates the long-term movement in the share price of a stock. When it comes to operating performance, GameStop has been a dud.</p>\n<p>Although the company's first-quarter fiscal results highlighted a 25% net sales increase from the prior-year period, total sales for the company have been falling precipitously for years. That's because video game retailer GameStop recognized the shift to digital gaming too late, and it's now stuck with its massive portfolio of brick-and-mortar gaming stores. Even though e-commerce sales have been a bright spot for the company, slashing costs and closing stores remains its No. 1 priority.</p>\n<p>With sufficient cash, bankruptcy isn't a concern for GameStop. But without any true top-line growth and the company still losing money, it's an impossible sell at its current price tag.</p>\n<p><img src=\"https://static.tigerbbs.com/c7ff785aa0040a5565d474390f58b47a\" tg-width=\"700\" tg-height=\"457\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Ocugen: Implied downside of 18%</h3>\n<p>Volatile clinical-stage biotech stock <b>Ocugen</b> (NASDAQ:OCGN) may also be in for an unpleasant next 12 months. The company behind an experimental COVID-19 vaccine (Covaxin) and a trio of internally developed eye-blindness candidates is expected to shed 18% of its value, if Wall Street's consensus price target is correct.</p>\n<p>Arguably the biggest issue for Ocugen is the clinical update the company issued on June 10 concerning Covaxin. Even though partner Bharat Biotech led a large clinical study in India that yielded an overall efficacy of 78%, along with 100% efficacy in preventing severe forms of COVID-19, Ocugen announced on June 10 that it would forgo seeking an EUA in the U.S. and would instead file for a biologics license application. In other words, Ocugen's path to a quick emergency approval in the U.S. just flew out the window.</p>\n<p>What's more, the U.S. Food and Drug Administration's requested additional information and data on Covaxin. This is a fancy of saying that Ocugen will very likely have to run a clinical study in the U.S. prior to submitting Covaxin for approval. That means added costs and an even longer wait before Ocugen has a chance to penetrate the lucrative U.S. market.</p>\n<p>Though it's impossible to predict how long COVID-19 vaccine immunity will last, Ocugen's chances of being a significant player in the U.S. COVID-19 vaccine space are dwindling.</p>\n<p><img src=\"https://static.tigerbbs.com/91f6037829ea3fb0ae1cae0b95d8d11e\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>NVIDIA: Implied downside of 3%</h3>\n<p>Don't adjust your computer, laptop, or smartphone screens -- that really says <b>NVIDIA</b> (NASDAQ:NVDA). Following its incredible run higher (NVIDIA has doubled over the past year), graphics processing unit giant NVIDIA closed 3% above Wall Street's consensus price target, as of June 17.</p>\n<p>One reason for tempered expectations at this point has to be valuation. Even with NVIDIA crushing expectations and seeing strong PC gaming demand, sales growth is expected to slow from an estimated 49% in fiscal 2022 to a high single digit percentage in each of the next two fiscal years. In fact, the company closed at nearly 20 times projected sales for the current fiscal year. That's a bit optimistic given an expected sales growth slowdown.</p>\n<p>Perhaps the other reason Wall Street expects NVIDIA to go sideways is the company's cryptocurrency mining chip segment. While sales of crypto chips could hit $400 million in the current quarter, demand is entirely dependent on the hype surrounding digital currencies and the favorability of technical charts. Crypto is just as well known for its long bear markets as it is for the big gains it's delivered over the past decade. If another lull strikes, a fast-growing ancillary segment for NVIDA could easily become a drag.</p>\n<p>For what it's worth, I see no fundamental reasons to sell NVIDIA if you're already a long-term shareholder. But if you're on the outside looking in, I don't exactly see $746 as an attractive entry point, either.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Stocks Wall Street Views as Overvalued</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Stocks Wall Street Views as Overvalued\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 21:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/21/5-ultra-popular-stocks-wall-street-view-overvalued/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Generally speaking, it pays to be bullish on Wall Street. Despite navigating its way through Black Monday in 1987, the dot-com bubble, the Great Recession, and more recently the coronavirus crash, the...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/21/5-ultra-popular-stocks-wall-street-view-overvalued/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PLTR":"Palantir Technologies Inc.","GME":"游戏驿站","NVDA":"英伟达","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/21/5-ultra-popular-stocks-wall-street-view-overvalued/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145084835","content_text":"Generally speaking, it pays to be bullish on Wall Street. Despite navigating its way through Black Monday in 1987, the dot-com bubble, the Great Recession, and more recently the coronavirus crash, the average annual total return for the benchmark S&P 500 since 1980, including dividends, is north of 11%.\nNot surprisingly, we see this optimism readily apparent in Wall Street's ratings on stocks. According to FactSet, more than half of all stocks carry a consensus buy rating, 38% have the equivalent of a hold rating, and just 7% are rated as sells. Yet, history shows that far more than 7% of stocks will eventually head lower.\nBased on Wall Street's consensus price targets, the following five ultra-popular stocks are all expected to lose value over the coming 12 months.\n\nImage source: Getty Images.\nPalantir Technologies: Implied downside of 12%\nSince its direct listing in late September 2020, data-mining company Palantir Technologies (NYSE:PLTR) has been a favorite among growth and retail investors. But if Wall Street's one-year consensus price target proves accurate, Palantir will head in reverse by up to 12%.\nThe likeliest reason Wall Street is tempering expectations on Palantir is valuation. Specifically, Palantir ended June 17 with a market cap of nearly $48 billion, but is on track to bring in perhaps $1.5 billion in full-year sales in 2021. That's a multiple of about 32 times sales. Even if Palantir continues to grow its top-line at 30% annually, it could take years for this price-to-sales multiple to come down to anywhere close to the average for cloud stocks.\nAnother possible concern is the growth potential for its government-focused Gotham platform. Big government contract wins in the U.S. have been primarily responsible for Palantir's exceptional growth rate. However, there remains an outside chance that President Joe Biden may curb funding to some of the federal agencies that employ Palantir's services.\nOver the long run, I'm optimistic and believe Palantir's platform is unlike anything else available. But tempering near-term expectations given its valuation premium may be warranted.\n\nImage source: Getty Images.\nModerna: Implied downside of 11%\nBiotech stock Moderna (NASDAQ:MRNA) is arguably the biggest beneficiary of the coronavirus disease 2019 (COVID-19) pandemic. It's one of only three drugmakers to currently have their COVID-19 vaccine approved on an emergency-use authorization (EUA) basis in the United States. But if Wall Street's consensus 12-month price target is correct, it's stock is also on its way to a double-digit decline.\nWhy the lack of love from Wall Street? The answer looks to be analysts looking to the future. While Moderna's COVID-19 vaccine is a mainstay in the U.S., and it's likely to play a clear role in other markets, time might prove the company's enemy. Over time, new vaccines are expected to come onto the scene, which'll eat away at Moderna's potential pool of patients.\nThe other worry is that no one is exactly certain how long COVID-19 vaccine immunity will last. If it's a year, Moderna is unlikely to be the only drugmaker supplying booster shots. Meanwhile, if it's longer than a year, it means reduced sales opportunities for the company.\nBased solely on Wall Street's earnings per share consensus in 2021 and 2022, Moderna appears reasonably priced. But with the company staring down a potentially significant haircut in revenue next year as new drugmakers enter the space, caution is advised.\n\nImage source: Getty Images.\nGameStop: Implied downside of 71%\nThis will probably come as a shock to no one, but Reddit favorite GameStop (NYSE:GME) is fully expected to fall flat on its face. Even though Wall Street's consensus price target for the company has quintupled in recent months, it still implies up to 71% downside over the next year.\nThe biggest issue for GameStop is that its valuation has completely detached from its underlying fundamentals. While it's not uncommon for stocks to trade on emotion for short periods of time, operating performance is what always dictates the long-term movement in the share price of a stock. When it comes to operating performance, GameStop has been a dud.\nAlthough the company's first-quarter fiscal results highlighted a 25% net sales increase from the prior-year period, total sales for the company have been falling precipitously for years. That's because video game retailer GameStop recognized the shift to digital gaming too late, and it's now stuck with its massive portfolio of brick-and-mortar gaming stores. Even though e-commerce sales have been a bright spot for the company, slashing costs and closing stores remains its No. 1 priority.\nWith sufficient cash, bankruptcy isn't a concern for GameStop. But without any true top-line growth and the company still losing money, it's an impossible sell at its current price tag.\n\nImage source: Getty Images.\nOcugen: Implied downside of 18%\nVolatile clinical-stage biotech stock Ocugen (NASDAQ:OCGN) may also be in for an unpleasant next 12 months. The company behind an experimental COVID-19 vaccine (Covaxin) and a trio of internally developed eye-blindness candidates is expected to shed 18% of its value, if Wall Street's consensus price target is correct.\nArguably the biggest issue for Ocugen is the clinical update the company issued on June 10 concerning Covaxin. Even though partner Bharat Biotech led a large clinical study in India that yielded an overall efficacy of 78%, along with 100% efficacy in preventing severe forms of COVID-19, Ocugen announced on June 10 that it would forgo seeking an EUA in the U.S. and would instead file for a biologics license application. In other words, Ocugen's path to a quick emergency approval in the U.S. just flew out the window.\nWhat's more, the U.S. Food and Drug Administration's requested additional information and data on Covaxin. This is a fancy of saying that Ocugen will very likely have to run a clinical study in the U.S. prior to submitting Covaxin for approval. That means added costs and an even longer wait before Ocugen has a chance to penetrate the lucrative U.S. market.\nThough it's impossible to predict how long COVID-19 vaccine immunity will last, Ocugen's chances of being a significant player in the U.S. COVID-19 vaccine space are dwindling.\n\nImage source: Getty Images.\nNVIDIA: Implied downside of 3%\nDon't adjust your computer, laptop, or smartphone screens -- that really says NVIDIA (NASDAQ:NVDA). Following its incredible run higher (NVIDIA has doubled over the past year), graphics processing unit giant NVIDIA closed 3% above Wall Street's consensus price target, as of June 17.\nOne reason for tempered expectations at this point has to be valuation. Even with NVIDIA crushing expectations and seeing strong PC gaming demand, sales growth is expected to slow from an estimated 49% in fiscal 2022 to a high single digit percentage in each of the next two fiscal years. In fact, the company closed at nearly 20 times projected sales for the current fiscal year. That's a bit optimistic given an expected sales growth slowdown.\nPerhaps the other reason Wall Street expects NVIDIA to go sideways is the company's cryptocurrency mining chip segment. While sales of crypto chips could hit $400 million in the current quarter, demand is entirely dependent on the hype surrounding digital currencies and the favorability of technical charts. Crypto is just as well known for its long bear markets as it is for the big gains it's delivered over the past decade. If another lull strikes, a fast-growing ancillary segment for NVIDA could easily become a drag.\nFor what it's worth, I see no fundamental reasons to sell NVIDIA if you're already a long-term shareholder. But if you're on the outside looking in, I don't exactly see $746 as an attractive entry point, either.","news_type":1},"isVote":1,"tweetType":1,"viewCount":455,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125848226,"gmtCreate":1624669199165,"gmtModify":1633949878384,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Apple","listText":"Apple","text":"Apple","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/125848226","repostId":"2146071375","repostType":4,"isVote":1,"tweetType":1,"viewCount":450,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167163294,"gmtCreate":1624252677118,"gmtModify":1634008833695,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Nice piece of info!","listText":"Nice piece of info!","text":"Nice piece of info!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167163294","repostId":"1124609704","repostType":4,"repost":{"id":"1124609704","kind":"news","pubTimestamp":1624238429,"share":"https://www.laohu8.com/m/news/1124609704?lang=&edition=full","pubTime":"2021-06-21 09:20","market":"fut","language":"en","title":"Gold Steadies After Posting Biggest Weekly Loss in 15 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1124609704","media":"bloomberg","summary":"Gold steadied after posting the biggest weekly loss in 15 months as the Federal Reserve’s hawkish sh","content":"<p>Gold steadied after posting the biggest weekly loss in 15 months as the Federal Reserve’s hawkish shift damped reflation bets.</p>\n<p>Inflation risksmay warrantthe U.S. central bank beginning raising interest rates next year, St. Louis Fed President James Bullard said Friday. His comments came after last week’s Fed meeting where officials signaled monetary policy tightening could start earlier than expected, with Chair Jerome Powell saying that the Fed would begin a discussion about scaling back bond purchases used to support financial markets and the economy during the pandemic.</p>\n<p><img src=\"https://static.tigerbbs.com/fc269bfd6438429e7f1bd15ec2aa60a1\" tg-width=\"930\" tg-height=\"523\" referrerpolicy=\"no-referrer\"></p>\n<p>Bullion has been weighed down by concerns over tighter monetary policy, although Powellcautionedthat discussions about raising interest rates would be “highly premature.” He’s due to testify at a House Subcommittee hearing on the Fed’s pandemic emergency lending and its asset purchase programs Tuesday.</p>\n<p>Spot gold rose 0.2% to $1,768.45 an ounce at 7:24 a.m. in Singapore. Prices fell 6% last week, the most since March 2020. Silver, palladium and platinum all advanced. The Bloomberg Dollar Spot Index steadied after rising 2% last week.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gold Steadies After Posting Biggest Weekly Loss in 15 Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGold Steadies After Posting Biggest Weekly Loss in 15 Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 09:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-06-21/gold-steadies-after-posting-biggest-weekly-loss-in-15-months><strong>bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gold steadied after posting the biggest weekly loss in 15 months as the Federal Reserve’s hawkish shift damped reflation bets.\nInflation risksmay warrantthe U.S. central bank beginning raising ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-21/gold-steadies-after-posting-biggest-weekly-loss-in-15-months\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GOLD":"巴里克黄金"},"source_url":"https://www.bloomberg.com/news/articles/2021-06-21/gold-steadies-after-posting-biggest-weekly-loss-in-15-months","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124609704","content_text":"Gold steadied after posting the biggest weekly loss in 15 months as the Federal Reserve’s hawkish shift damped reflation bets.\nInflation risksmay warrantthe U.S. central bank beginning raising interest rates next year, St. Louis Fed President James Bullard said Friday. His comments came after last week’s Fed meeting where officials signaled monetary policy tightening could start earlier than expected, with Chair Jerome Powell saying that the Fed would begin a discussion about scaling back bond purchases used to support financial markets and the economy during the pandemic.\n\nBullion has been weighed down by concerns over tighter monetary policy, although Powellcautionedthat discussions about raising interest rates would be “highly premature.” He’s due to testify at a House Subcommittee hearing on the Fed’s pandemic emergency lending and its asset purchase programs Tuesday.\nSpot gold rose 0.2% to $1,768.45 an ounce at 7:24 a.m. in Singapore. Prices fell 6% last week, the most since March 2020. Silver, palladium and platinum all advanced. The Bloomberg Dollar Spot Index steadied after rising 2% last week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":270,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187118943,"gmtCreate":1623746210482,"gmtModify":1634029218468,"author":{"id":"3553149584675358","authorId":"3553149584675358","name":"FORTISTRYER","avatar":"https://static.tigerbbs.com/ab36eda6ee73b54496452df68d33cead","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3553149584675358","authorIdStr":"3553149584675358"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187118943","repostId":"1175897310","repostType":4,"repost":{"id":"1175897310","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623725513,"share":"https://www.laohu8.com/m/news/1175897310?lang=&edition=full","pubTime":"2021-06-15 10:51","market":"us","language":"en","title":"IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings","url":"https://stock-news.laohu8.com/highlight/detail?id=1175897310","media":"Benzinga","summary":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is ","content":"<p>This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.</p>\n<p><b>AMTD Digital:</b>Asian digital solutions platform&nbsp;<b>AMTD Digital</b>(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.</p>\n<p><b>Molecular Partners:</b>Clinical stage biotechnology company&nbsp;<b>Molecular Partners</b>(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;<b>Novartis</b>(NYSE:NVS) in 2020,<b>Amgen Inc</b>(NASDAQ:AMGN) in 2018 and&nbsp;<b>AbbVie Inc</b>(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.</p>\n<p><b>WalkMe:</b>With a mission to change the way humans interact with technology,<b>WalkMe</b>(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.</p>\n<p>WalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.</p>\n<p><b>Convey Holding:</b>Health care company&nbsp;<b>Convey Holding</b>(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.</p>\n<p><b>Angel Oak Mortgage:</b>Real estate finance company&nbsp;<b>Angel Oak Mortgage</b>(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.</p>\n<p><b>Lyell Immunopharma:</b>Seeking to disrupt the T-cell reprogramming market,<b>Lyell ImmunoPharma</b>(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered with<b>GlaxoSmithKline</b>(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.</p>\n<p>GlaxoSmithKline owns 14% of Lyell and&nbsp;<b>Bristol-MyersSquibb</b>(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.</p>\n<p><b>Verve Therapeutics:</b>Genetic medicine company<b>Verve Therapeutics</b>(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.</p>\n<p><b>Atai Life Sciences:</b>Backedby&nbsp;<b>Palantir Technologies</b>(NYSE:PLTR) and&nbsp;<b>Paypal Holdings</b>(NASDAQ:PYPL) founder Peter Thiel,<b>Atai Life Sciences</b>(NASDAQ:ATAI) could be one of the high profile IPOs of the week.</p>\n<p>The company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.</p>\n<p><b>AiHui Shou International:</b>Pre-owned consumer electronics reseller&nbsp;<b>AiHuiShou International</b>(NYSE: RERE)seeksto give a second life to all idle goods.</p>\n<p>The company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.<b>JD.com</b>(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-15 10:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.</p>\n<p><b>AMTD Digital:</b>Asian digital solutions platform&nbsp;<b>AMTD Digital</b>(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.</p>\n<p><b>Molecular Partners:</b>Clinical stage biotechnology company&nbsp;<b>Molecular Partners</b>(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;<b>Novartis</b>(NYSE:NVS) in 2020,<b>Amgen Inc</b>(NASDAQ:AMGN) in 2018 and&nbsp;<b>AbbVie Inc</b>(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.</p>\n<p><b>WalkMe:</b>With a mission to change the way humans interact with technology,<b>WalkMe</b>(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.</p>\n<p>WalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.</p>\n<p><b>Convey Holding:</b>Health care company&nbsp;<b>Convey Holding</b>(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.</p>\n<p><b>Angel Oak Mortgage:</b>Real estate finance company&nbsp;<b>Angel Oak Mortgage</b>(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.</p>\n<p><b>Lyell Immunopharma:</b>Seeking to disrupt the T-cell reprogramming market,<b>Lyell ImmunoPharma</b>(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered with<b>GlaxoSmithKline</b>(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.</p>\n<p>GlaxoSmithKline owns 14% of Lyell and&nbsp;<b>Bristol-MyersSquibb</b>(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.</p>\n<p><b>Verve Therapeutics:</b>Genetic medicine company<b>Verve Therapeutics</b>(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.</p>\n<p><b>Atai Life Sciences:</b>Backedby&nbsp;<b>Palantir Technologies</b>(NYSE:PLTR) and&nbsp;<b>Paypal Holdings</b>(NASDAQ:PYPL) founder Peter Thiel,<b>Atai Life Sciences</b>(NASDAQ:ATAI) could be one of the high profile IPOs of the week.</p>\n<p>The company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.</p>\n<p><b>AiHui Shou International:</b>Pre-owned consumer electronics reseller&nbsp;<b>AiHuiShou International</b>(NYSE: RERE)seeksto give a second life to all idle goods.</p>\n<p>The company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.<b>JD.com</b>(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RERE":"万物新生","ATAI":"ATAI Life Sciences B.V.*","LYEL":"Lyell Immunopharma, Inc.","HKD":"尚乘数科","NVS":"诺华","MOLN":"Molecular Partners AG","WKME":"WalkMe Ltd.","AOMR":"ANGEL OAK MORTGAGE REIT INC"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175897310","content_text":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform AMTD Digital(NYSE:HKD) offers risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company Angel Oak Mortgage(NYSE: AOMR) acquiresand invests in first lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby Palantir Technologies(NYSE:PLTR) and Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","news_type":1},"isVote":1,"tweetType":1,"viewCount":211,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}